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ABSTRACT
Predictors and Health Outcomes of Treatment-Resistant Depression
among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder
Drishti Shah
Understanding major depressive disorder (MDD) as a comorbidity in patients with chronic noncancer pain conditions (CNPC) is of importance because of the high prevalence and well
documented bi-directional relationship between MDD and pain. Furthermore, presence of CNPC
among adults with MDD often reduces benefits of antidepressant therapy, thereby increasing the
possibility of treatment resistance. Treatment-resistant depression (TRD) commonly defined as
insufficient response to multiple antidepressant trials, often worsens depression and pain
symptoms and can amplify the clinical and economic burden among adults with CNPC and
MDD. Additionally, long-term opioid therapy (LTOT) may be prescribed at a higher rate to
adults with TRD to treat an undifferentiated state of physical and mental pain, despite lack of
evidence on LTOT use in this patient population. Existing literature on TRD has focused on all
adults with MDD. Owing to the lack of research on TRD among adults with CNPC and MDD,
we conducted this study to fill a critical knowledge gap. This dissertation pursued three related
aims: 1) identify leading predictors of TRD; 2) estimate the direct economic burden associated
with TRD and identify factors that contribute to the excess cost burden of TRD; and 3) examine
the trajectory of LTOT use in adults with CNPC and newly diagnosed MDD and how TRD can
alter this trajectory. The study used a retrospective, longitudinal, cohort design, using multiple
years (2007-2017) of the de-identified, geographically diverse data on commercially insured
adults obtained from the 10% random sample of Optum® Clinformatics® Data Mart. TRD was
identified using a comprehensive claims-based algorithm. Among adults (>18 years) with CNPC
and newly diagnosed MDD who were treated with antidepressants (N=23,645), approximately
one in nine adults transitioned to TRD within a year of MDD diagnosis. First, we identified the
use of mental health specialist visits, polypharmacy, psychotherapy use, anxiety, and age to be
the five leading predictors of TRD using random forest, a machine learning method and crossvalidated logistic regression. In the second aim, we observed that patients with TRD had
significantly higher direct all-cause ($21,015TRD vs. $14,712No TRD) and MDD-related costs
($1,201TRD vs. $471No TRD), and healthcare resource utilization (e.g. IRR for inpatient visits =
1.30. 95% CI = 1.14-1.47; P<0.001) as compared to those without TRD. Majority of excess total
healthcare costs among adults with TRD were driven by differences in rates of polypharmacy
between the TRD and non-TRD groups. Lastly, findings from the third aim indicated that adults
with TRD were more likely to receive LTOT [AOR: 1.54, 95% CI: 1.68-2.04), although LTOT
use among TRD group declined over the three-year observation period, at a higher rate than
those without TRD (β= -.033, SE=0.012). In summary, these findings underscore the need for
effective, evidence-based strategies to manage depression and pain among adults with TRD and
CNPC. In addition, the current study identified modifiable factors that warrant further
investigation and may serve as potential targets for clinical and policy interventions to reduce the
risk of TRD and off-set the excess costs associated with TRD. Furthermore, high rates of LTOT
use among adults with TRD suggest that clinicians need to closely monitor the risks of using
LTOT in this subgroup.
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CHAPTER 1
1 Introduction
1.1 Background and Significance
Epidemiology of Major Depressive Disorder
Major Depressive Disorder (MDD) is the leading cause of disability worldwide, and is a
major contributor to the burden of suicide.1 MDD is highly prevalent and affects approximately
35 million adults in the United States (US).2,3 Among adults in US, MDD accounts for nearly 3.7
percent of all disability-adjusted life years (DALYs) and 8.3 percent of all years lived with
disability (YLDS).4 MDD disproportionately affects women; women are 70% more likely to
experience MDD during their lifetime than men. As per the National Comorbidity Study, the
lifetime prevalence of MDD in the US was estimated to be 21.3% in women and 12.7% in men.5
It has been reported that MDD is significantly associated with increased risk of other psychiatric
disorders, notably anxiety disorders, substance use disorders and other chronic conditions such as
chronic non-cancer pain conditions (CNPC).2, 6,7 MDD also plays a significant role in worsening
functional status, with the greatest impairment in the social and cognitive domains.2
Burden of MDD
MDD is associated with significant clinical, humanistic, and economic burden.1,8 It is
projected to cause the greatest illness burden in high-income countries by 2030.9 In 2015, the
incremental economic burden of MDD in the US was estimated to be as high as $210.5 billion,
with $98.9 billion spent on direct healthcare costs.8 Co-existence of MDD and other chronic
conditions has been reported to be the main driver of this high economic burden associated with
MDD.8 For example, MDD is associated with 50% to 100% higher medical costs among patients
with co-existing chronic conditions even after risk adjustments.10 Among commonly co-
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occurring chronic conditions with MDD, chronic non-cancer pain conditions (CNPC) is of
particular interest because of the high prevalence and well documented bi-directional
relationship between MDD and pain.7,11
MDD among Adults with Chronic Non-cancer Pain Conditions
Of all the chronic conditions that can co-exist or develop in MDD patients, commonly
occurring CNPC including, back/neck pain, headache/migraine, and neuropathic pain conditions
deserve special attention because of the special pathophysiology between MDD and CNPC.
Link between MDD and CNPC
MDD and painful symptoms, commonly experienced by adults with CNPC often cooccur together. 7,12 MDD and its treatment can be affected by pain, which is also considered as a
somatic symptom of depression.13 A growing body of literature has documented the bidirectional relationship between chronic pain and MDD. As pain and MDD are inextricably
linked in terms of the shared biological pathways and neurotransmitters, they often respond to
similar treatments, and exacerbate one another. Some researchers have labeled this relationship
as depression-pain syndrome.14,15 It has been suggested that one of the important causes for
chronic pain leading to depression and vice versa appears to be the common neuroplasticity
changes shared by pain and depression such as changes in monoamine neurotransmitters, brainderived neurotrophic factor, inflammatory factors, and glutamate functions.16
Prevalent MDD among Adults with CNPC
Given that pain is often experienced by adults with CNPC, several studies have examined
the prevalence of MDD in patients with CNPC. A narrative review on MDD and pain
summarized the prevalence of MDD in adults with CNPC and reported that the estimated
prevalence of MDD in patients with CNPC can be as high as 85%. 7 However, depending on the

2

type of condition and setting,7 MDD prevalence can range from 38% in psychiatric clinics, 52%
in pain clinics, 56% in orthopedic or rheumatology clinics, and to 85% in dental clinics.7
Treatment-Resistant Depression among Adults with MDD
A significant proportion of the economic and clinical burden of MDD is
disproportionately accounted by individuals who do not achieve recovery from the illness.
Consensus exists that a majority of individuals (nearly 50%) do not achieve complete remission
with index antidepressant therapy. The designation -“treatment-resistant depression (TRD)” is
primarily used to describe patients who do not respond to more than two adequate trials of
antidepressants.17-20 The STAR*D trial, the largest and longest study ever conducted to evaluate
the effectiveness of depression treatment reported that even after undergoing four sequential
antidepressant trials, 30% of patients did not achieve remission.21 Due to the variations in TRD
definitions in studies using administrative claims or similar datasets, the prevalence of TRD has
ranged from 6%22 to 30%.23
High risk of TRD among Adults with CNPC and MDD
CNPC may contribute to TRD among adults with MDD. Biar et al investigated the
presence of pain conditions on treatment response to depression in primary care.11 They
concluded that the presence of baseline CNPC among adults with MDD reduces the benefits of
antidepressant therapy at 12 weeks, suggesting treatment resistance.11 Indirect evidence of the
relationship between CNPC and TRD has been reported. A Canadian Study by Rizvi et al. and a
US study by Kubitz et al. reported that the prevalence of CNPC such as joint pain, muscle pain,
headache/migraine, and back pain was two times higher among patients with TRD as compared
to those without TRD.22,24 It is plausible that adults with CNPC may be at higher risk of having
TRD, because pain experienced by those with CNPC may reduce the efficacy of antidepressant
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therapy. 11 However, to date, no study has systematically examined the risk of TRD among
adults with CNPC and MDD, suggesting a significant need for studies on TRD among adults
with CNPC. In this context, the first critical step in filling this knowledge gap is an examination
of risk factors that influence the transition from MDD to TRD among adults with CNPC.
Risk Factors for TRD among Adults with CNPC and MDD
TRD can be influenced by biological, health- and treatment- related factors. In studies
not specific to CNPC, it has been reported that women (71%), non-Hispanic whites (89%), adults
with comorbid conditions (for example, CNPC, cardiovascular diseases, hypertension, and other
psychiatric conditions), obesity, highly activated inflammatory system, and patients who are
hospitalized were more likely to experience TRD compared to those without these risk factors.
20,22,24,25

Recent studies conducted using predictive models to identify risk factors of TRD using

data obtained through the Group for the Study of Resistant Depression (GSRD), across
participating centers in Europe concluded that depression severity, age, time span between first
and last depressive episodes, suicidal risk, body mass index, number of past depressive episodes,
and lifetime duration of hospitalizations were important predictors of TRD.26-28 It has to be noted
that these studies included prevalent cases of MDD and therefore, the identified factors may not
be plausible risk factors for TRD among patients with newly diagnosed MDD. Another study
that sought to find risk factors of TRD among patients with newly diagnosed MDD reported that
patients with TRD were more likely to be younger, have a history of substance use disorders,
psychiatric conditions, insomnia, and pain as compared to non-TRD patients. 29 However, to
date, no study has identified risk factors of TRD among adults with CNPC and newly diagnosed
MDD.
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As the current study focused on adults with CNPC and MDD, in addition to the above
factors, association of treatment factors with TRD, such as pain therapy commonly used for
CNPC needs to be investigated. It has been reported that effective pain treatment can relieve
depressive symptoms 36,37 and may therefore reduce the risk of TRD. On the other hand, type of
pain treatment can positively or negatively impact TRD. For example, opioid use may increase
the risk of TRD. A retrospective study on the dose and duration of opioid therapy on TRD
among Veterans reported that longer duration of opioid treatment increased the risk of
transitioning from MDD to TRD.30 Pain treatment with nonsteroidal anti-inflammatory drugs
(NSAIDs) may improve depression outcomes among adults with specific CNPC such as
osteoarthritis.31,32 As the long term use of opioids in patients with CNPC is not effective, 33,34
there is critical a need to assess the association of other pain therapies such as the use of
NSAIDs, and other non-pharmacological pain therapies such as psychotherapy with TRD. Since
psychotherapies such as cognitive behavioral therapies are effective for treating both MDD and
chronic pain, they may reduce the risk of TRD.35
The current study also included factors that have not been examined in other studies such
as polypharmacy. It has been documented that the concurrent use of 3 or more medications with
depression as an adverse event may increase the risk of having concurrent MDD.36 Additionally,
certain commonly used medications (e.g. benzodiazepines, corticosteroids, and beta-blockers,
and certain muscle relaxants) have higher rates of drug-drug interactions with antidepressants
and dilute plasma concentration of antidepressants, which may lead to poor clinical response and
TRD.37 Therefore, polypharmacy as a predictor of TRD needs to be investigated.
Early identification of leading predictors of TRD in real-world clinical settings with
robust statistical and machine leaning methods can inform targeted treatment approaches. As
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these predictive models require a large of number of observations, population-based claims data
can be ideal.38,39 This leads to the rationale for Aim 1, which examined the risk factors of
transitioning from MDD to TRD among adults with CNPC and newly diagnosed MDD.
Role of TRD in Amplifying Burden of MDD
A review on the disease burden of TRD highlighted that the number of medicationrelated adverse events were higher and the quality of life scores were 26 points lower for adults
with TRD when compared to those adults with MDD who experienced remission.20 Additionally,
adults with MDD also incur a higher economic burden due to TRD. Those with TRD have an
excess annual direct healthcare cost of $5,461 per patient and an additional $4,048 per patient in
productivity losses. Extrapolating these costs to national level yielded an estimated $29-$46
billion due to TRD (depending on the prevalence estimates of 12 and 20 percent respectively),
thereby pushing up the total societal costs of MDD to as high as $106-$118 billion.20 The burden
of TRD is on par with or even higher than other medical conditions such as cancer and diabetes,
yet MDD ranks 15th among conditions that receive funding from the National Institutes of
Health,40 thereby underscoring the need for more research on TRD.
Economic Burden of TRD
Nearly one-third of the excess cost of MDD has been attributed to TRD.20 Among
working-age adults with MDD, several studies have quantified the direct healthcare utilization
and costs associated with TRD. 22,23,25,30,41-45 Although the reported incremental economic burden
of TRD varied depending on the definition of TRD and type of study setting; on an average,
working age adults with TRD had two times higher direct healthcare costs as compared to those
without TRD. 23,25,41,42 A recent study that estimated the cost burden of TRD reported that adults
with TRD incurred $6,709 and $9,917 higher per patient per year costs as compared to non-TRD
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adults with MDD and non-MDD patients.46 Furthermore, those with TRD also had significantly
higher odds of using inpatient, outpatient and ER services.23,25,22 However, none of these existing
studies have estimated the economic burden of TRD among adults with CNPC. A population
based study that did not focus on TRD concluded that the presence of concomitant pain
conditions in patients with MDD initiated 20% higher visits to medical providers than those with
MDD but no pain conditions.47 Presence of TRD can further amplify this burden.
Understanding the relationship between TRD and healthcare costs and utilization among
a specific subgroup of patients with CNPC can provide meaningful information to payers and
policy makers on how patients’ MDD and pain-related complexity can affect healthcare resource
use. Given limited healthcare resources, healthcare costs have always been an essential measure
of health outcomes in the US. In response to the rising healthcare costs, the Institute of Health
Improvement developed the “Triple Aim” which requires identification of high-cost, high-need
patients. 48 Therefore, such cost of illness studies are important not only to provide benchmark
for evaluation of alternative demands on scarce health care resources, but also help in translating
the burden of illness into dollar terms, the universal language for decision making.49 As there are
no cost estimates on TRD among adults with CNPC and MDD, estimates obtained from the
current study can be used as input parameters in future cost-effectiveness studies.
Furthermore, as highlighted above, TRD can be influenced by many factors. 20,27,29,50
Identification of key contributors of the incremental TRD burden using advanced decomposition
methods can assist policy makers in assessing if the limited healthcare resources are being
inequitably used and can aid payers in identifying major cost drivers. This leads to the rationale
for Aim 2, which estimated the incremental economic burden (direct healthcare utilization and
costs) associated with TRD among adults with CNPC and newly diagnosed MDD. In addition, a
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post-regression decomposition approach was adopted to explain patient level factors that may
contribute to the difference in total healthcare costs between adults with and without TRD.
Role of TRD in the trajectory of pain treatment with opioids among adults with CNPC
As stated before, pain is a hallmark symptom of CNPC and is also a somatic symptom of
MDD.7,11 It difficult to manage pain among patients with CNPC and MDD for several reasons:
1) patients with co-existing CNPC and MDD report higher pain scores as compared to those with
CNPC but no MDD;51 2) increased difficulty in managing chronic pain and MDD may come
with patients that also have substance use disorders. For example, it has been reported that
patients with MDD are 1.8-2.4 times likely to misuse opioid medications;53) patients with MDD
and pain report higher impairment in functional capacity; 4) depression severity increases when
pain is more diffuse, as indicated by multisite pain, often experienced by patients with CNPC.52
As adults with co-existing CNPC and MDD may experience pain at higher intensity
which may not be responsive to first line pain therapies such as NSAIDs, opioids may be
prescribed for longer duration. There has been a growing need to examine the risks of long-term
opioid therapy (LTOT) among patients with CNPC due to the concern that the safety and
effectiveness of LTOT in CNPC remains unproven.53,54 Further, no treatment guidelines
recommend LTOT for patients with CNPC who also have MDD.55 Yet patients with CNPC and
MDD continue to receive LTOT in real-world settings. 55 As MDD often makes chronic pain
worse among adults with CNPC, 11patients with MDD and chronic pain may often preferentially
seek relief for their pain, which may be less stigmatized. Health care providers may be obligated
to prescribe medications such as opioids to treat the undifferentiated state of physical and mental
pain in these patients. In fact, patients with MDD in real-world are more likely to receive LTOT
than those without MDD diagnoses.56
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As patients with TRD experience worse depression symptoms and physical symptoms
such as pain as compared to those without TRD,26 LTOT may be prescribed at a higher rate
among patients with TRD. TRD may increase the use of LTOT55 as the neural patterns of
activation that are associated with depression are also associated with pain, and LTOT may be
prescribed to treat the complex combination of both pain and TRD.55,57 In addition, historically
opioids have been used to treat psychological distress caused by mental health conditions.5,58
LTOT in patients with TRD may further exacerbate the risk of opioid misuse leading to
detrimental consequences such as death due to overdose, intentional harm, and suicide.1,5 On the
other hand, clinicians may be more cautious in prescribing LTOT to MDD patients who develop
TRD. This is because this group of patients may be deemed to be a high- risk group as both
LTOT and TRD are independently associated with increased risk of substance use disorders and
adverse health outcomes. 30, 3220,22 While, there is evidence that patients with MDD and pain are
more likely to receive LTOT,56,59,60 and LTOT may increase the risk of TRD,30 to date, no study
has examined the trajectory of LTOT use among patients with CNPC and MDD and how TRD
may alter this trajectory.
The central question in prescribing LTOT for CNPC and TRD is how to best balance the
risk of opioid abuse and dependence. The first critical step in answering this question is an
understanding of the pattern of LTOT prescription among adults with CNPC and MDD and the
association of TRD with the trajectory of LTOT use. Robust evidence on the pattern of LTOT
use among adults with CNPC and MDD and any efforts to understand the risk factors of LTOT
are useful in the broader context of battling the current opioid epidemic. Findings from the
current study can inform clinical practice, payers, and policy makers in their surveillance efforts
of controlling long- term opioid use and misuse. Therefore, a study examining the trajectory of
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LTOT in adults with CNPC and newly diagnosed MDD and the association of TRD with LTOT is
needed, thereby justifying the rationale for aim 3 of the current study.
1.2 Innovation
a) Comprehensive evaluation of risk factors associated with TRD among adults with
CNPC and newly diagnosed MDD: This is the first study to conduct comprehensive
analyses of biological, health- and treatment- related factors associated with TRD among
adults with CNPC and newly diagnosed MDD using a large, geographically diverse
dataset of commercially insured adults.
b) Use of a comprehensive and nuanced claims-based algorithm to identify adults with
TRD in a unique population of adults with CNPC and MDD: The current study
applied a comprehensive claims-based algorithm, developed using the Massachusetts
General Hospital (MGH) clinical staging method. 23,61 This algorithm has been previously
used by Gibson et al. to identify adults with TRD and estimate the cost burden of TRD
among adults with MDD. 23 Several existing studies have defined TRD based on a single
criterion or a combination of criteria such as number of antidepressant switches, number
of titrations, and concomitant administration of antidepressants, mood stabilizers or
atypical antipsychotics. 22,29,30,46 Unlike approaches based on a single criterion, the MGH
scoring based approach used in this study is comprehensive as it includes the four main
strategies to overcome lack of response i.e. optimization, switching, combination or
augmentation. 62 Further this approach can be easily translated to prescription data
available in pharmacy claims.23 To date, no study has used this approach to identify TRD
among adults with CNPC and MDD.
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c) Novel risk factors of TRD: As the current study specifically focuses on adults with
MDD and CNPC, it used several novel risk factors of TRD such as polypharmacy, type
of pain treatment, and number of CNPC conditions. Association of these risk factors with
TRD has not been established in previous studies on adults with MDD.
d) Fill a significant knowledge gap in literature: Given that no studies have examined
TRD among adults with co-existing CNPC and MDD, the proposed study will fill an
important knowledge gap in literature by identifying leading predictors of TRD,
quantifying excess economic burden associated with TRD and examining the association
between TRD and LTOT.
e) Use of advanced predictive modeling to identify leading predictors of TRD using
routinely collected insurance claims data: use of predictive modeling to identify
patients who are at risk for transitioning from MDD to TRD among individuals with
CNPC will help in understanding modifiable factors which can guide clinicians in
intervening early to reduce the risk of TRD. Additionally, targeted interventions can be
designed for this sub-group of patients to improve clinical outcomes and reduce future
medical costs and, healthcare utilization.
f) Application of econometric techniques to identify the difference in characteristics
between patients with and without TRD that explain the excess total healthcare
expenditures associated with TRD: This is the first study to examine the contribution of
various patient level differences between adults with TRD and without TRD to the
observed gap in total healthcare costs between the two groups from a population based
perspective.
1.3 Specific Aims
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AIM 1: Identify leading predictors of transitioning from MDD to TRD among adults with
CNPC and newly diagnosed MDD in a real-world setting using a machine learning
approach.
Hypothesis: In adjusted models, that include all the predictors, presence of chronic
conditions, anxiety disorders, sleep disorders, substance- use disorders, age, and
polypharmacy will be leading predictors of TRD among adults with CNPC and newly
diagnosed MDD.
AIM 2: Estimate the direct economic burden (direct healthcare costs and utilization) of
TRD and its contributory factors among adults with CNPC and newly diagnosed MDD
using post-regression decomposition techniques.
Hypothesis: Adults with TRD will have significantly higher direct healthcare costs and
utilization as compared to adults without TRD; the majority of excess costs due to TRD
will be explained by differences in the type of CNPC, presence of obesity, sleep disorders,
and other chronic conditions between the two groups.
AIM 3: Examine the trajectory of LTOT over a 3-year period in adults with CNCP and the
association of TRD with LTOT among adults with CNPC and newly diagnosed MDD.
Hypothesis:The use of LTOT will decline over the 3-year study period and adults with TRD
will be more likely to use LTOT as compared to adults without TRD.
1.4 Approach
Conceptual Framework
Aim 1: Extensive literature review and a conceptual framework adapted from the modified
determinants of health outcomes and chronic disease model was used to identify the plausible
risk factors of TRD.63 This framework was originally proposed by Wilkinson and Marmot.63
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The model suggests that incidence of a disease (in this case TRD) can be affected by several
dimensions. These dimensions include: 1) community resources (e.g. geographical region), 2)
access to care factors (e.g. Medicare enrollment, type of plan and co-pay), 3) treatment- related
factors (e.g. pain treatment such as opioid use, NSAID use, use of psychotherapy, type of
provider such as primary care provider, specialist, mental health specialist, polypharmacy, class
of index antidepressant medication, and inpatient status), 4) biological risk factors (e.g. age, sex),
and 5) health-related factors which comprises of two sub-domains, mainly chronic health
conditions (e.g. CVD, hypertension, diabetes, asthma, COPD, anxiety disorders, dementia, sleep
disorder, osteoporosis, and type of CNPC), and lifestyle factors (e.g. substance use, tobacco use,
alcohol use and obesity).

Figure 1.1: Adapted determinants of health outcomes and chronic disease model
Aim 2: The conceptual framework for Aim 2 was based on the adapted Andersen’s
Behavioral Model of Health Services Use,64 which posits that healthcare utilization of an
individual is a function of multiple factors. These factors can be grouped into four domains,
13

including 1) predisposing factors that represent the individual characteristics predictive of using
healthcare services (e.g., age, sex); 2) enabling factors that may enable access to healthcare
services (e.g. Medicare advantage enrollment, type of insurance plan); 3) need factors that define
an individual’s health status (e.g. chronic conditions, obesity, sleep disorders, tobacco use
disorder, and substance use disorder, polypharmacy, benzodiazepine use, and use of pain
medication such as opioids and NSAIDs); and 4) environmental factors that may influence an
individual’s healthcare utilization (e.g. geographical region).
Aim 3: To guide the process of variable selection for aim 3 of the current study, the
expanded Symptom Management Model was used.65,66 The generic symptom management
model has three dimensions: symptom experience, management strategies and outcomes. The
dimension of symptom experience can be described as perception of symptom as well as a
response to a symptom. As per the proposed framework, presence of TRD, which is mainly nonresponse to depression treatment trials, was considered as a symptom which can influence the
outcome of LTOT. As per the model, the above dimensions are influenced by the following three
domains: (1) the personal domain, which comprised of demographic factors (e.g. age, sex,
insurance plan type, Medicare advantage enrollment), psychological factors (e.g. presence of
anxiety and other mental health comorbidities); (2) the health and illness domain (e.g. chronic
physical conditions, obesity, sleep disorders, substance use disorders, polypharmacy,
benzodiazepine use, and use of pain medication such as NSAIDs); (3) the environmental domain
(e.g. geographical region, index year of MDD diagnosis).
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Figure 1.2 Expanded Symptom Management Model
Data Sources
To accomplish the study objectives, we used the 10% sample of de-identified health
insurance claims data from Optum Clinformatics ® DataMart (Optum Clinformatics®, Eden
Prairie, MN, USA) for the period of 1st January 2007 through 30th June 2017. This nationally
representative, geographically diverse database contains a combination of inpatient, outpatient
and pharmacy claims for individuals enrolled in the commercial insurance plans and Medicare
Advantage plan of a large U.S. health insurance company. The data also contains information on
lab results, certain demographic characteristics (e.g year of birth, sex, residential state) and plan
type (e.g. health maintenance organization, preferred provider organization, point of service, feefor-service )that are routinely collected during health insurance enrollment.67 The data contains a
10% random sample of information on 47 million individuals, approximately 80% of whom
purchased insurance from their employers.
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CHAPTER 2
2 Predictors of Treatment-Resistant Depression among Adults with Chronic Non-Cancer
Pain Conditions and Major Depressive Disorder: A Machine Learning Approach
2.1 Abstract
Objective: Presence of chronic non-cancer pain conditions (CNPC) among adults with major
depressive disorder (MDD) often reduces benefits of antidepressant therapy, thereby increasing
the possibility of treatment resistance. This study sought to identify leading predictors of
treatment-resistant depression (TRD) among adults with newly diagnosed MDD and CNPC
using machine learning approaches.
Methods: This retrospective cohort study included adults (>18 years) with newly diagnosed
MDD and CNPC from a de-identified 10% random sample of Optum® Clinformatics® Data
Mart (2007-2017). TRD was identified using the Massachusetts General Hospital clinical staging
algorithm for claims data. Random forest (RF), a machine learning method, was used to identify
leading predictors of TRD. Initial model development included 42 known and/or probable risk
factors for TRD. The final refined model included 20 risk factors. To facilitate comparison with
published studies, results from logistic regression are presented.
Results: Included in the sample were 23,645 patients (73% female mean age: 55 years; 78%
with >2 CNPC, and 91% with joint pain/arthritis). Overall, 11.4% (N = 2,684) transitioned from
newly diagnosed MDD to TRD. The five leading predictors of TRD were: mental health
specialist visits, polypharmacy (>5 medications), psychotherapy use, anxiety, and age. Crossvalidated logistic regression model indicated that those with TRD were younger, more likely to
have anxiety, mental health specialist visits, polypharmacy, and psychotherapy use with AORs
ranging from 1.9-1.3 (all Ps < 0.01).
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Conclusion: Machine learning identified several modifiable factors that warrant further
investigation and may serve as potential targets for clinical intervention to improve treatment
outcomes in those with TRD.
2.2 Introduction
Major Depressive Disorder (MDD) affects approximately 350 million adults worldwide
and 35 million adults in the United States (US).3,68 Major Depressive Disorder is the leading
cause of disability and a major contributor to the overall global illness burden.1,69 Despite the
efficacy of various antidepressant medications in improving depression symptoms, many adults
with MDD in real-world settings do not respond to repeated trials of antidepressants. 70,71
Therefore, a significant proportion of the burden of MDD can be attributed to treatment resistant
depression (TRD).20 Although there is lack of consensus on the definition of treatment resistant
depression (TRD), the designation -“TRD” is primarily used to describe patients who do not
respond to at least two adequate trials of antidepressants.17-20,72 Due to the variations in study
population, follow-up time period, datasets used, and measures used to define TRD, the
prevalence of TRD has ranged from 6%22 to 30%21 in published studies. For example, the
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, the largest and longest
study ever conducted to evaluate the effectiveness of depression treatment reported that even
after undergoing four sequential antidepressant trials, 30% of patients did not achieve
remission.21,72
Published studies have suggested that some subgroups of patients with MDD may be
more likely to have TRD.20,22,24,29 These studies have consistently reported higher prevalence of
TRD among adults with chronic non-cancer pain conditions (CNPC). 20,22,24,29 It is plausible that
individuals with CNPC may be more likely to transition into TRD because MDD and its
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treatment can be affected by pain, often considered as a somatic symptom of depression.13 A
growing body of literature has documented the bi-directional relationship between pain and
MDD. As pain and MDD are inextricably linked in terms of the shared biological pathways and
neurotransmitters, they often respond to similar treatments, and may also exacerbate one another.
Some researchers have labeled this relationship as depression–pain syndrome.14,15 A narrative
review on MDD and pain estimated that the prevalence of MDD in patients with CNPC can be as
high as 85% and can range from 32%-85% depending on the type of condition and setting.7 A
study by Biar et al. concluded that presence of baseline CNPC among adults with MDD reduces
the benefits of antidepressant therapy at 12 weeks, suggesting treatment resistance.11 Indirect
evidence of the relationship between CNPC and TRD has been reported. A Canadian Study by
Rizvi et al. and a US study by Kubitz et al. reported that the prevalence of CNPC such as joint
pain, muscle pain, headache/migraine, and back pain was two times higher among patients with
TRD, as compared to those without TRD.22,24
The transition from MDD to TRD can be influenced by many factors. In studies not
specific to CNPC, severity of depression, response to first antidepressant treatment, number of
past depressive episodes, obesity, highly activated inflammatory system, inpatient status,
presence of anxiety, insomnia, pain, and other social factors have been identified as risk factors
of TRD20,22, 26,28,29,50,73,74 While there is literature on risk factors of TRD among general
population with MDD, among a sub-group of adults with CNPC and MDD, additional probable
risk factors such as pain therapy commonly used for CNPC needs to be examined. Certain
commonly used analgesic medications and other medications such as benzodiazepines,
corticosteroids, and beta-blockers may have mood related adverse effect or have higher rates of
drug-drug interactions with antidepressants which can lead to safety concerns, poor clinical
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response, and may increase the risk of TRD.36,37 As adults with CNPC are more likely to have
polypharmacy, the potential for drug-drug interactions may be greater with severe health
consequences.75,76 Therefore, polypharmacy as a predictor of TRD needs to be investigated.
To our knowledge, to date, no study has systematically examined the risk of TRD among
adults with CNPC and MDD. In this context, the first critical step in filling this knowledge gap is
an examination of risk factors that can influence the transition from MDD to TRD among adults
with CNPC. When a patient is newly diagnosed with MDD, the presence of characteristics that
could increase the risk of TRD may alert healthcare providers to monitor the patients more
closely. Identification of leading predictors of TRD in real-world clinical settings with robust
statistical and machine leaning methods can help clinicians understand treatment response and
inform targeted individualized treatment approaches. Furthermore, non-parametric machine
learning methods can improve predictive accuracy by reducing over fitting even in the presence
of complex interactions, as compared to standard parametric approaches. 77As these predictive
models require a large of number of observations and predictors, population-based claims data
can be ideal.38,39 Therefore, the primary objective of the study is to identify leading predictors of
transitioning from MDD to TRD among adults with CNPC and newly diagnosed MDD in a realworld setting using a machine learning approach.
2.3 Methods
Study design and Data Source
We used a retrospective cohort study design. The cohort included all adults (age > 18
years) with newly diagnosed MDD and CNPC. We used de-identified patient data with medical
and pharmacy claims as well as enrollment information from the Optum® Clinformatics® Data
Mart67 for the period January 2007 to June 2017. For this study, we used a 10% random sample
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extracted from a nationally representative, geographically diverse database of 47 million
individuals. The data comprised adults who were insured in a commercial plan as well as
Medicare Advantage plans. 67
Newly diagnosed MDD was identified between January 2008 and June 2016 using a
validated and published algorithm.78,79 The first observed MDD diagnosis during a calendar year
was identified using ICD-9-CM (International Classification of Diseases, Ninth Revision,
Clinical Modification) or ICD-10 CM (International Classification of Diseases, Tenth Revision,
Clinical Modification) diagnosis codes as appropriate (See in Appendix 7.1). A 180-day lookback period was used to ensure that the individuals did not have any MDD claims or
antidepressant prescriptions.
The date of newly diagnosed MDD (index date) was used to create the baseline period (12
months before the index date) and the follow-up period (12 months after the index date). The
baseline period was used to identify CNPC and other predictors (see Measures section). The
follow-up period was used to identify TRD and MDD treatment-related factors during the acute
phase of treatment, before TRD identification (first 90 days after MDD diagnosis) (Appendix
7.2).
Analytical Sample
The analytical sample consisted of adults with CNPC identified in the 12 months before
MDD diagnosis. CNPC was identified using an extensive list of 1000 conditions for which pain
was severe enough to call them as CNPC.80-82 The diagnoses were further collapsed into four
major pain categories: arthritis/joint pain, back/neck pain, headache/migraine, and neuropathic
pain/other chronic pain conditions. 80-82 We required at least two healthcare encounters in an
inpatient or outpatient setting for identification of adults with CNPC. The ICD 9/10 diagnosis
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codes used to identify CNPC are provided in the Appendix 7.2. Other inclusion/exclusion criteria
were: at least one antidepressant prescription after MDD diagnosis; continuous enrollment
during the baseline and follow-up period (24 months); no cancer diagnosis at any time during the
study period; and consistent with prior studies, individuals having any diagnosis of
schizophrenia, schizoaffective disorder, other psychosis, manic depression or bipolar disorders
were excluded. 22,23 The final analytical sample consisted of 23,645 adults with CNPC and newly
diagnosed MDD (See Figure 1 for number of individuals eliminated at each step of
inclusion/exclusion criteria).
Outcome
Treatment-Resistant Depression
The primary outcome was the transition to TRD within a year after the index date.
Identification of TRD using insurance claims data is challenging for several reasons: 1) there is
no universally accepted definition of TRD; 2) lack of information on depression symptoms and
severity; and 3) availability of prescription rather than actual use of antidepressants. 42 Therefore,
studies using administrative claims have used several different algorithms to define TRD. These
have typically included single criterion such as number of antidepressant switches, number of
titrations, concomitant administration of antidepressants, mood stabilizers or atypical
antipsychotics, or a scoring method based on all of the above. 22,23,41,42 Additionally, use of
electroconvulsive therapy is also considered as a marker of TRD because ECT is often used as a
late-stage treatment for TRD.41
We applied the Massachusetts General Hospital (MGH) clinical staging method to insurance
claims to identify individuals with TRD. This algorithm has been previously used to predict the
cost burden of TRD 23,61 We selected this algorithm because it includes the four main strategies
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to overcome lack of therapeutic response, i.e. optimization, switching, combination or
augmentation and can be easily translated to prescription data available in pharmacy claims.62
Using this approach, we assigned 1 point for each adequate antidepressant trial (i.e., two or more
fills of the same antidepressant), half a point for each of the following optimization strategy:
extended duration defined as > 3 fills of the same antidepressant, an upward titration in dose, and
augmentation with atypical antipsychotic/mood stabilizer. An overall score exceeding three was
used as a threshold to establish TRD and those with a score exceeding three were classified as
having TRD.23An MGH score of three is the equivalent to two distinct antidepressant trials with
one optimization strategy such as augmentation.29 Any additional optimization or augmentation
strategy would meet the threshold for TRD.83 Those using electroconvulsive therapy (ECT) were
considered to have TRD.
Statistical and Prediction Analyses
Unadjusted associations between predictors and TRD were examined using chi-square
tests for categorical variables and t-tests for continuous varibles. Multivariable logistic regression
(LR), a method familiar to many researchers is a standard technique for analysis of binary
outcomes in medicine and social science, where the focus is not only on prediction, but also on
explaining the association between variables.84 Logistic regression, a standard parametric method
makes several assumptions about the data.84 Recently, algorithmic or machine learning methods
that do not have any strong parametric assumptions have gained popularity because they can be
used on large complex datasets and can provide better accuracy.85 A common theme among all
the algorithmic models is validation and testing of models using random bootstrap samples.
Although many types of machine learning methods are available for binary outcomes such as the
presence or absence of TRD, random forest (RF) is a particulary attractive alternative because of
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its many advantages such as high predictive accuracy, reduction in overfitting, and identification
of most useful set of features. RF is based on decision trees, which represent the relationships of
variables in the dataset. Each decision tree models hierarchical relationships between predictors
and outcomes by maximing the amount of information gain.
We used the caret and randomForest package for R software for building the machine
learning predictive models using LR and RF.86 To create and train the models the data was
randomly split into a 70% training sample (N=16,570) and was internally validated using a 30%
test sample (N=7,075). The training sample was used for model refinement, learning, and to
determine the model coefficients, while the test sample was used to evaluate the model
performance on a previously unseen data.
RF requires input of the number of decision trees to grow for each run and the number of
features to be used for each tree. After model training and tuning, the number of trees for each
run was determined to be 100 and the number of features was set to five. The trained fully
adjusted model and the model with top 20 predictors were then tried in the test data and
prediction accuracy was computed for the treatment outcome. The area under the curve (AUC)
was calculated to assess the performance of the predicting models and measures of
discrimination, including sensitivity and specificity are reported. To facilitate model
interpretation, the adjusted odds ratio and their 95% confidence intervals computed from
performing logistic regression of the final model are presented for the top predictors identified
from the machine learning method. Dataset construction was performed using SAS 9.4 (Cary,
NC) and all predictive modeling was performed in R software (R Development Core Team,
Vienna, Austria).
Predictors (i.e. Features) of TRD for Inclusion in the Model

23

While feature selection can be performed using automated methods, many experts
suggest that variable selection should be supported by expert knowledge or conceptual
frameworks, whenever feasible.87 Initial selection of the plausible predictors of TRD (n=42) was
based on the Determinants of Health Outcomes and Chronic Disease conceptual framework,63
that included the following dimensions: 1) biological risk factors, 2) access to care factors (e.g.
type of plan and co-pay), 3) disease and health- related factors 4) treatment-related factors
(MDD-related treatment, pain-related treatment, and other treatment factors), and 5) community
resources. For a comprehensive list of all predictors see Table 2.1. While most variables were
measured during the baseline period, MDD-treatment related variables were measured during the
follow-up period, before TRD measurement. In order to ensure that all included variables were at
least plausible predictors of TRD, a manual variable selection was performed using an extensive
literature review and a conceptual framework adapted from the modified Determinants of Health
Outcomes and Chronic Disease conceptual framework. 63
Biological factors included age and sex. Predictors included in access to care domain
were the type of plan, and out of pocket payment (calculated using co-pay, co-insurance and
deductible for healthcare services). Disease-related factors included type and number of CNPC
and health-related factors included other chronic conditions, obesity, substance use disorders
(including tobacco use disorder, alcohol use disorder, and drug use disorders). All health-related
factors were measured using ICD-9 or ICD-10-CM codes as appropriate. Pain-related treatment
factors included commonly used pain medications such as opioid use, and NSAID use. MDDrelated treatment factors included mental health specialist visits, inpatient status, use of
psychotherapy after MDD diagnosis, and class of index antidepressant medication. Other
treatment-related factors included primary care provider visits, polypharmacy (defined as
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concomitant use of > 5 medications within 90 days)88, and use of medications that may have
depression as a side-effect (included fills for benzodiazepines, analgesics such as NSAIDs and
opioids, statins, corticosteroids, and beta blockers).36
Model Development
To identify an abbreviated set of factors that can increase the utility of the predictive
model for providers and other stakeholders, a more refined model was built using basic filter
method such as chi-square for categorical variables and pearson’s correlation for continuous
variables. Further, an alternative wrapper feature selection method using logistic regression was
used, wherein the performance of regression models with subsets of variables is assessed in
random subsets of data.89 Feature selection yielded a total of 20 variables for inclusion in the
refined model. Figure in the Appendix 7.3 illustrates the process of variable selection and model
development.
2.4 Results
Characteristics of the study sample (total N=23,645) are summarized in Table 2.2.
Majority were females (73.3%) and the mean age of patients was 55.36 years. Arthritis/joint pain
was the most commonly observed pain condition (91%) followed by back/neck pain (71%). A
large proportion of study sample reported > 2 CNPC conditions (78%). The most commonly
observed other chronic conditions were cardiovascular conditions (38.4%) and anxiety (27.6%).
About one forth of the study subjects used pain medications such as opioids (28.7%) and
NSAIDs (25.5%).
In our study sample, 2,684 patients (11.4%) had TRD within one year after MDD
diagnosis. About 3.3% of the study sample augmented antidepressants with an atypical
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antipsychotic or a mood stablizer and only 11 patients were found to be using electroconvulsive
therapy within one year of MDD diagnosis. (Supplementary Information, Appendix 7.4)
There were statistically significant differences in TRD status (Table 2.2) by age, type and
number of CNPC, other chronic conditions such as anxiety, presence of sleep disorders,
substance use disorders, polypharmacy, and use of MDD-related treatment factors (All p <
0.001). For example, the prevalence of TRD was significantly higher among younger adults (3544 years old) as compared to those with age > 65 years (13.0% vs. 9.2%), among those with
anxiety (15.3% vs. 9.9%), with >3 CNPC conditions (14.1% vs. 9%) as compared to those with
one CNPC. A significantly higher proportion of adults with TRD had drug use disorder (19.8%
vs. 11.0%), used polypharmacy (14.9% vs. 8.5%), and benzodiazepines in the baseline period
(15.4 % vs. 9.8%). Additionally, greater proportions of adults having inpatient hospitalizations,
and mental health specialist visits within 90 days of MDD diagnosis had TRD as compared to
those having no inpatient or mental health specialist visits (p < 0.001). Adults who were
prescribed SSRI as the first antidepressant after MDD diagnosis had lower prevalence of TRD,
whereas those whose index prescription belonged to the class of other antidepressants and TCAs
had higher prevalence of TRD (p < 0.001).
The fully-adjusted predictive model as well as the reduced predictive model with top 20
features had fairly modest discriminatory model performance. The AUC obtained from the RF
model for the training data was 0.716 and 0.70 for the fully-adjusted and refined models
respectively. The out of bag (OOB) error, which is an indicator of the unbiased estimator of true
error rate, ranged from 11.4% -11.5%. Similar model performance was observed in the test data
(Supplemental information, Appendix 7.5). The AUC for the RF and LR models were similar.
The AUC from the training sample for the fully adjusted LR model was 0.711 for the fully-
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adjusted model and 0.704 for the refined model and from the test sample for the fully adjusted
and refined models was 0.708 and 0.705 respectively.
The average importance values obtained from LR and RF for the highest scoring top 10
predictors of TRD are represented in Figure 2. Overall, mental health specialist visits,
polypharmacy, psychotherapy use, presence of anxiety, younger age, index antidepressant class,
sex, any IP hospitalization after MDD diagnosis, number of CNPC, and benzodiazepine use were
the leading predictors of TRD in both RF and LR, although ordering were slightly different.
For ease of interpretation and for comparison with published literature, Table 2.3
summarizes the adjusted odds ratios (AOR) and their associated 95% CIs obtained from logistic
regression of the final refined model (model with top 20 features). For example, adults visiting
mental health specialists within 90 days of MDD diagnosis were almost two times more likely to
develop TRD, as compared to those not having mental health specialist visits (AOR = 1.93; 95%
CI = 1.7-2.18). Adults using psychotherapy after MDD diagnosis (AOR=1.36, 95% CI=1.201.55) and those using > 5 different types of medications concomitantly in a period of 90 days
(AOR=1.81, 95% CI=1.62-2.03) were more likely to develop TRD, as compared to their
counterparts without these characteristics.
2.5 Discussion
To our knowledge, this is the first study using large administrative claims data to identify
leading predictors of TRD among commercially insured adults CNPC and newly diagnosed
MDD. In the current study, approximately one in nine adults (11.4%) with CNPC and newly
diagnosed MDD transitioned to TRD within 1 year. This estimate is consistent with previously
reported estimates for TRD prevalence among adults with MDD which ranged from 6% to
30%.22,23,29,44 It has to be noted that TRD rates from our study are not directly comparable to
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published studies due to differences in study population as our study sample was restricted to
adults with CNPC and newly diagnosed MDD. Our estimate of 11.4% for TRD prevalence,
which was identified using a clinical staging claims algorithm,23,61 was in line with a recent
study that reported the prevalence rate of TRD as 11% using the Optum database. It has to be
noted that the previous study used a slightly different definition for identifying TRD subjects as
those with at least three distinct trials of antidepressants or those who augmented antidepressants
with antipsychotics.29
Consistent with published literature we found age to be a leading predictor of TRD.29,30 It
has been reported in literature that TRD has been linked to an earlier age of onset of
depression,90,91 and our study findings further support this. Sex has not been previously reported
as a leading predictor of TRD. 26,27,29,50 However, the relevance of sex in this patient population
is not new.22, 51, 55 This finding could perhaps be attributed to the higher prevalence and risk of
both MDD as well as chronic pain among females, as compared to males.22,30,92 It has to be noted
that our study sample was overwhelmingly female (73%), which is comparable to the 61% -71%
prevalence estimates of females in studies conducted among all adults with MDD.22,29,41
Our findings demonstrated that in clinical settings, a smaller set of MDD treatmentrelated factors around the time of MDD diagnosis can be used to predict the risk of transitioning
from MDD to TRD. These included the class of first prescribed antidepressant after MDD
diagnosis, mental health specialist visits, and psychotherapy use within the first 90 days after a
MDD diagnosis. Specifically, we found that adults with CNPC who used SSRIs, the most
frequently prescribed antidepressants,93 as their index antidepressant were less likely to transition
from MDD to TRD. Existing studies on association between the specific type of antidepressants
and outcomes in patients with TRD had a very small sample size and resulting conclusions
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should be taken cautiously.74 In light of the findings from the current study, future research is
warranted to understand the association between types of antidepressants with TRD. The
predictors such as mental health specialist visits and psychotherapy use are often indicative of
greater depression severity.94As patients with more severe MDD or patients with poor response
to antidepressants may have a higher chance of visiting a mental health specialist or using
psychotherapy as additional treatment,94 they may have a higher risk of TRD.
The current study identified anxiety as well as benzodiazepine to be predictors of TRD.
While, comorbid anxiety disorder has been consistently reported by several studies as a risk
factor for TRD, 26,74,90,91 association of benzodiazepine use with TRD has not been investigated
in prior literature. Treatment becomes challenging when pain, often experienced by those with
CNPC and MDD, overlap with anxiety. Researchers have highlighted the reciprocal interactive
relationships between pain, anxiety and depression.51,91 It is plausible that anxiety is a risk factor
for TRD because comorbid anxiety disorder and MDD in patients with CNPC is often associated
with higher symptom severity and poor response to depression treatment.51,91 Benzodiazepines
are commonly used medications for anxiety and sleep disorders, both common comorbid
conditions among patients with CNPC and MDD. In fact, studies have shown that the use of
benzodiazepines is significantly higher among patients with chronic pain.95,96 Previous research
has documented a high prevalence of benzodiazepine use among women, especially older
women, and among opioid users.97,98 Despite several major medical and psychiatric
organizations advising against using benzodiazepines among elderly and in combination with
opioids, benzodiazepines continue to be prescribed. This may lead to high risks and serious
adverse effects among vulnerable groups.99, 96 Benzodiazepine use as a predictor of TRD further
reinforces the need to weigh the risk versus benefits of prescribing benzodiazepines among
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adults with CNPC and newly diagnosed MDD. Our findings suggest that patients with CNPC,
MDD and anxiety disorders need to be monitored more closely and that there is a need for
evaluating alternative treatment strategies that can help in the co-management of these
conditions.
We also identified the number of CNPC conditions as an important predictor of TRD.
Higher number of CNPC conditions may indicate multisite chronic pain and may result in
increased pain severity which is a strong predictor of poor depression outcomes.11 Studies have
also reported that chronic pain was associated with increased severity of depression and
insufficient response to antidepressants.11,100 Several large clinical trials on chronic pain often
exclude patients with MDD, 101 and therefore lack of data on treatments that can be used to comanage both pain and MDD continues. Our findings underscore the need for effective
pharmacological treatments for managing both pain and MDD symptoms.
Our predictive models identified polypharmacy (excluding the use of antidepressants) as
one of the top five predictors of TRD. Pain medications are commonly used to relieve pain
among patients with CNPC. While we did not find individual pain medications such as NSAIDs
and opioids as risk factors for TRD, a combination of medications may increase the potential
exposure to side-effects and harm due to drug-drug interactions. In fact, a recent study which
characterized polypharmacy among patients with CNPC suggested that a majority of medication
related-harm exposure was also attributed to medications other than opioids, such as simple
analgesics, benzodiazepines, and number of medications used concomitantly.75 Higher number
of concomitant medication use is also indicative of the presence of multiple chronic conditions
which are more common in patients with TRD, as compared to those without TRD.20
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Although machine learning methods and standard logistic regression method yielded
similar model performance, adoption of RF and LR machine learning approaches enabled us to
perform robust feature selection and in identifying the most important predictors out of an
extensive set of 40 features. The model performance of fully adjusted as well as with a reduced
set of 20 variables was comparable and fairly modest. A reduced set of top n features (n=20)
helps in focusing on the most important predictors of TRD and is more practical if one was to
design a new study and collect features to predict TRD among CNPC patients.
2.6 Limitation
Although a rigorous methodology was utilized to design and execute the study, the
findings of this study need to be interpreted in the context of its limitations. The study suffers
from inherent limitations associated with claims data analysis, including coding inaccuracies,
absence of information on severity of MDD, socioeconomic status, race/ethnicity, physical
activity, and social support. Furthermore, our algorithm used to identify MDD naïve patients (a
look-back period of 180 days) may not truly capture all incident MDD patients. For patients
having multiple MDD episodes in the study period, we selected the very first episode, however,
it is possible that they could have received diagnosis or treatment elsewhere, which could not
have been captured in the current claims. It has to be noted that lack of availability of severity of
MDD and pain may have resulted in unobserved selection bias. Further, we may not have truly
captured the actual use of prescription medication as the drug claims provide information on only
filled prescriptions and not actual use.
Although we identified leading predictors of TRD in a sample of CNPC patients with
newly diagnosed depression, the model had a much better discriminative power to predict nonTRD cases as compared to TRD cases. One plausible explanation is that published prediction
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models with better sensitivity to identify TRD cases used data from participating clinical centers
across Europe or clinical trial data which predicted TRD among prevalent cases of MDD. This
can provide information on the number of past depressive episodes, severity of MDD, and other
clinical parameters which could not be captured via administrative claims data.26-28,73
Additionally, in actual clinical practice, adults with TRD are identifying using detailed clinical
criteria such as responsiveness to medical treatments, and tolerance to antidepressants, which
were not available in claims data. Therefore, we may have either underestimated or
overestimated the prevalence of TRD. The models were refined and tested in unique sub-sample
that was created from the same overall sample as the training data. The validity of the model and
the leading predictors obtained from the models will be more generalizable if applied to datasets
with patients with CNPC obtained from different samples, specifically other commercial
administrative databases.
2.7 Conclusion
Notwithstanding the limitations, our study provides important insights on factors that
may predict the transition from MDD to TRD among patients with CNPC using a large
population-based real-world study. We identified biological and health-related factors unique to
CNPC who developed MDD such as number of CNPC conditions, age, sex, other chronic
conditions such as anxiety, polypharmacy and factors related to MDD treatment and severity
such as mental health specialist visits, use of psychotherapy, and class of index antidepressant as
leading predictors of TRD. These factors can serve as targets for future studies to further
understand TRD and can help in developing healthcare and clinical interventions to improve
treatment outcomes in patients with CNPC and MDD.
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Figure 2.1 Schematic presentation of study sample selection-Inclusion and exclusion
criteria applied to patients with CNPC and newly diagnosed episode of MDD, Optum
Clinformatics Data Mart, observation period January 2007-June 2017.
Patients with MDD in years 2008-2016
N=683,701
Those with MDD but no
CNPC (N=412,208)

N=683,701
Patients with CNPC diagnosis in baseline period
N=271,493
Had cancer (N=69,538)
Cancer Free
N=201,955
Patients with conditions
that could complicate TRD
assessment (N=9,627)
Patients without schizophrenia, schizoaffective,
manic depression or bipolar disorder
N=192,328
Patients without incident
MDD (N=101,391)
Patients with newly diagnosed MDD episode
(No MDD diagnosis or antidepressant
prescription in prior 180 days)
N=90,937

Patients receiving antidepressant treatment (at
least 1 antidepressant fill after MDD diagnosis)
N=50,664

Final analytical sample: Patients aged >18
years with continuous enrollment 12 months
before and 12 months after the index date
N=23,645

With TRD
N=2,684

Without TRD
N=20,961
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Patients with no
antidepressant claims
(N=40,273)

Adults without continuous
enrollment (N=27,009)
and those with unknown
information on sex
variable (N=10)

Table 2.1. List of All 42 Predictors Considered for Model Inclusion Described by the Conceptual
Framework Dimensions
Dimension
Predictors
Biological risk factors (N=2)

Age, sex

Access to care factors (N=3)

Community resources(N=1)

Medicare enrollment, (commercial, Medicare advantage), plan type a (HMO,
PPO/POS, other), out of pocket payment
Type of CNPC (grouped into commonly occurring CNPC conditions including
back/neck pain, arthritis/joint pain, headache/migraine, neuropathic/other
chronic pain), number of CNPC conditions, chronic conditions including
anxiety, respiratory conditions (asthma and COPD), hypertension,
cardiovascular conditions b, dementia, diabetes, other mental illness,
osteoporosis, sleep disorder, obesity diagnosis, tobacco use disorder, alcohol
use disorder, drug use disorder
Pain – related treatment (included NSAID use, opioid use), use of
psychotherapy before MDD diagnosis, polypharmacy c, use of medications
associated with depression including benzodiazepines, corticosteroids, beta
blockers, and statins, primary care provider visits, mental health specialist
visits, use of psychotherapy after MDD diagnosis, any inpatient
hospitalizations, hospitalizations related to MDD, class of index antidepressant
(SSRI, SNRI, TCA, Other)d
geographical region (region derived from state variable)

Other predictors(N=1)

index year

Disease and Health-related
factors (N=18)

Treatment-related factors
(MDD -related, pain- related
and other treatment factors)
(N=17)

a HMO:

Health Maintenance Organization, PPO: Preferred provider organization, POS: Point of service, other plan
type includes fee-for-service, indemnity plans, EPO (exclusive provider organization), GPO (Group purchasing
organization), IPP (individual program plan), and other plans, CNPC: Chronic non-cancer pain conditions, NSAID:
Non-steroidal anti-inflammatory drugs
b
Cardiovascular conditions included hyperlipidemia, ischemic heart disease, coronary artery disease, congestive
heart failure, myocardial infarction, and stroke
c
Polypharmacy was defined as concomitant use of 5 or more medications within a 90-day period
d
SSRI: Selective serotonin reuptake inhibitors, SNRI: Serotonin norepinephrine reuptake inhibitors, TCA: tricyclic
antidepressants, other: includes medications such as bupropion, mirtazapine, nefazodone, trazadone, vilazodone, and
vortioxetine.
Note: MAOI (monoamine oxidase inhibitors) are not included as a predictor because of very small sample size
(N=4)
Note: Predictors related to MDD treatment such as use of psychotherapy, index antidepressant, mental health
specialist visits, hospitalizations were measured in acute phase of MDD treatment, i.e. first 90 days after MDD
diagnosis.
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Table 2.2. Description of Adults with CNPC and Newly Diagnosed MDD by TRD
Overall
(N=23,645)
Characteristics

N

%

Optum Clinformatics Real-World De-identified Data, 2007-2017
Overall
Patients classified as TRD (N=2,684)
(N=23,645)
Chi sq
Characterist
N
Row%
P value Sig
N
%
statistic
ics

Index Year

10.512

0.005

**

Patients classified as TRD
(N=2,648)
Chi sq
N
Row%
P value
statistic

Obesity diagnosis

2008-2010

6257

26.5

747

11.9

Yes

3842

16.2

458

11.9

2011-2013

7077

29.9

845

11.9

No

19803

83.8

2226

11.2

2014-2016

10311

43.6

1092

10.6

Sleep disorder

Region

6.289

0.098

Yes

5445

23

806

14.8

No

18200

77

1878

10.3

Northeast

2170

9.2

278

12.8

Midwest

5871

24.8

673

11.5

South

9544

40.4

1076

11.3

Yes

2399

10.1

346

14.4

West

6060

25.6

657

10.8

No

21246

89.9

2338

11

17340

73.3

2030

11.7

Yes

606

2.6

95

15.7

6305

26.7

654

10.4

No

23039

97.4

2589

11.2

Sex

Tobacco use disorder

8.181
Female
Male

Age group

57.418

18-34 years

3127

13.2

351

11.2

35-44 years

3616

15.3

470

13

45-54 years

4706

19.9

596

12.7

55-64 years

4468

18.9

554

12.4

>65 years

7728

32.7

713

9.2

Medicare Enrollment
Commercial
Medicare
Advantage
Insurance plan
type
HMO
PPO/POS

60.1

1645

11.6

9429

39.9

1039

11

31.5

819

11

11317

47.9

1319

11.7

***

Alcohol use disorder

Drug use disorder
No

975

4.1

193

19.8

22670

95.9

2491

11

Polypharmacy (>5 medications)

2.064
7439

<0.001

**

Yes

1.718

14216

0.004

0.19

Yes

10529

44.5

1566

14.9

No

13116

55.5

1118

8.5

NSAID use

0.356

Yes

6036

25.5

755

12.5

No

17609

74.5

1929

11

Yes

6789

28.7

760

12.6

No

16856

71.3

1790

11.5

Opioid use
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Sig

1.479

0.224

83.738

<0.001

***

25.03

<0.001

***

11.563

<0.001

***

72.05

<0.001

***

233.981

<0.001

***

10.783

0.001

**

5.188

0.023

*

Other

4889

20.7

546

11.2

Back/neck pain
Yes

30.475
16845

71.2

2034

12.1

6800

28.8

650

9.6

No
Headache/
migraine
Yes
No
Arthritis/Joint
Pain
Yes

7849

33.2

1051

13.4

15796

66.8

1633

10.3

91.1

2471

11.5

2110

8.9

213

10.1

Neuropathic pain/other chronic pain
5417

22.9

758

14

No

18228

77.1

1926

10.6

No. of CNPC
5217

22.1

469

9

2

10469

44.3

1095

10.5

>3

7959

33.7

1120

14.1

Anxiety
6520

27.6

996

15.3

No

17125

72.4

1688

9.9

Dementia
1058

4.5

169

16

No

22587

95.5

2515

11.1

703

3

153

21.8

22942

97

2531

11

Other mental illness
No

3003

12.7

435

14.5

No

20642

87.3

2249

10.9

Cardiovascular conditions

No

18850

79.7

2062

10.9

<0.001

***

Yes

6557

27.7

746

11.4

No

17088

72.3

1938

11.3

0.057

Yes

6550

27.7

1006

15.4

No

17095

72.3

1678

9.8

<0.001

***

Yes

2697

11.4

335

12.4

No

20948

88.6

2349

11.2

<0.001

***

Yes

1132

4.8

191

16.9

No

22513

95.2

2493

11.1

<0.001

***

Yes

4653

19.7

790

17

No

18992

80.3

1894

10

<0.001

***

Yes

5536

23.4

882

20.5

No

18109

76.6

1802

9.3

<0.001

***

Yes

19892

84.1

2194

11

No

3753

15.9

490

13.1

Any Inpatient hospitalizations†
33.582

Yes

13

Primary care provider visit†
78.067

Respiratory conditions

622

Mental health specialist visit†
23.516

Yes

20.3

Psychotherapy after MDD†
137.811

Yes

4795

Psychotherapy before MDD
95.738

1

Yes

Corticosteroid use
48.733

Yes

***

Benzodiazepine use
3.635

21535

<0.001

Statin use
48.543

No

Yes

Beta blocker use

<0.001

***

Yes

2593

11

453

17.5

No

21052

89

2231

10.6

MDD related Inpatient hospitalizations†
1.018

0.313

36

Yes

1116

4.7

227

20.3

No

22529

95.3

2457

10.9

15.698

<0.001

***

0.006

0.938

144.594

<0.001

3.463

0.063

36.021

<0.001

***

182.284

<0.001

***

437.948

<0.001

***

12.887

<0.001

***

108.362

<0.001

***

94.058

<0.001

***

***

Yes

9091

38.4

1008

11.1

No

14554

61.6

1676

11.5

Hypertension

1.028

Yes

9284

39.3

1078

11.6

No

14361

60.7

1606

11.2

Diabetes

0.081

Yes

4771

20.2

536

11.2

No

18874

79.8

2148

11.4

Osteoporosis
Yes
No

Index Antidepressant class:
SSRI†
Yes
12912

2.571
825

3.5

108

13.1

22820

96.5

2576

11.3

0.311

0.776

0.109

54.6

1019

7.9

No
10733
45.4
Index Antidepressant class: SNRI
†
Yes
3277
13.9

1665

15.5

388

11.8

No
20368
Index Antidepressant class:
TCA†
Yes
982

86.1

2296

11.3

4.2

167

17

No
22663
Index Antidepressant class:
Other†
Yes
5094

95.8

2517

11.1

No
Overall (N=23,645)
Continuous
variable
Age
Out of pocket
cost per month^

Patients classified with TRD
(N=2,684)

Mean

SD

Mean

SD

55.36

17.64

53.67

16.88

$928.68

$6,337

$933.30

$3,122.10

18551

21.5

926

18.2

78.5

1758

9.5

338.287

<0.001

***

0.903

0.342

32.558

<0.001

***

300.73

<0.001

***

Patients without TRD (N=20,961)
Mean
55.57
$928

SD

T statistic

P value

Sig

17.71

5.48

<0.001

***

$6,337.90

0.05

0.95

Note: Based on 23,645 adults with CNPC and newly diagnosed MDD receiving antidepressant medication treatment with continuous enrollment for 12 months baseline and 12 months
follow-up periods in a commercial insurance plan, years 2007-2017
MDD: Major Depressive Disorder, TRD: Treatment resistant depression, CNPC: Chronic non-cancer pain conditions, HMO: Health Maintenance Organization, PPO: Preferred provider
organization, POS: Point of service, other plan type includes fee-for-service, indemnity plans, EPO (exclusive provider organization), GPO (Group purchasing organization), IPP(individual
program plan), and other plans, NSAID: Non-steroidal anti-inflammatory drugs, SSRI: Selective serotonin reuptake inhibitors, SNRI: Serotonin norepinephrine reuptake inhibitors, TCA:
tricyclic antidepressants, other: includes medications such as bupropion, mirtazapine, nefazodone, trazadone, vilazodone, and vortioxetine.
Respiratory conditions included chronic obstructive pulmonary disease (COPD) and asthma
Cardiovascular conditions included hyperlipidemia, ischemic heart disease, coronary artery disease, congestive heart failure, myocardial infarction, and stroke
Polypharmacy was defined as concomitant use of 5 or more medications within a 90 day period
†Represents all MDD treatment related variables that were measured in the acute phase after MDD diagnosis i.e. first 90 days after MDD index date
^Average out of pocket costs are represented only for those incurred any out of pocket expenditure (N=13,752)
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05
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Figure 2.2 Variable importance values for top 10 variables of TRD among patients with
CNPC and newly diagnosed MDD obtained from Machine Learning Approaches: A)
Logistic regression B) Random forest models
Figure 2.2.A

Figure 2.2.B

Note: Predictors are listed on the Y axis by increasing impact of importance from the top to bottom.
CNPC: Chronic non-cancer pain conditions, IP: Inpatient, SSRI: Selective serotonin reuptake inhibitors
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Table 2.3. Adjusted Odds Ratio and 95% Confidence Intervals for Important Predictors of
TRD from Logistic Regression Model for Adults with CNPC and Newly Diagnosed MDD
Optum Clinformatics Real-World De-identified Data, 2007-2017
Predictor
AOR
95% CI
P value
Mental health provider visit (yes vs. no)
1.93 1.70-2.18
<0.001
Polypharmacy (yes vs. no)
1.81 1.62-2.03
<0.001
Use of psychotherapy after MDD diagnosis (yes vs.
1.36 1.20-1.55
<0.001
no)
Anxiety (yes vs. no)
1.27 1.13-1.41
<0.001
Age (35-44 years vs. ≥ 65 years) †
1.41 1.19-1.66
0.002
Age (18-34 years vs. ≥ 65 years) †
1.32
1.1-1.58
<0.001
Index Antidepressant class: SSRI (yes vs. no)
0.69 0.60-0.79
<0.001
Sex (female vs. male)
1.27 1.13-1.42
<0.001
Any IP hospitalization (yes vs. no)
1.26 1.11-1.48
<0.001
Index Antidepressant class: other (yes vs. no)
1.38
1.12-1.7
<0.001
No. of CNPC conditions (≥3 vs. 1)
1.23 1.09-1.39
<0.001
Benzodiazepine use (yes vs. no)
1.18 1.05-1.32
<0.001
Note: Based on 23,645 adults with CNPC and newly diagnosed MDD receiving antidepressant medication
treatment with continuous enrollment for 12 months baseline and 12 months follow-up periods in a
commercial insurance plan, years 2007-2017
MDD: Major Depressive Disorder, TRD: Treatment resistant depression, CNPC: Chronic non-cancer pain
conditions, SSRI: Selective serotonin reuptake inhibitors, other antidepressants: includes medications such
as bupropion, mirtazapine, nefazodone, trazadone, vilazodone, and vortioxetine, IP: Inpatient, AOR:
Adjusted odds ratio, CI: Confidence Interval
† Only age groups with p< 0.01 is presented
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CHAPTER 3
3 Economic Burden of Treatment-Resistant Depression among Adults with Chronic NonCancer Pain Conditions and Major Depressive Disorder
3.1 Abstract
Objective: Treatment-resistant depression (TRD) in adults with chronic non-cancer pain
conditions (CNPC) can amplify the economic burden. This study examined the impact of TRD
on direct total and MDD-related healthcare resource utilization (HRU) and costs among patients
with CNPC and MDD.
Methods: The study used a retrospective longitudinal cohort design and employed a claimsbased algorithm to identify adults with TRD from a US claims database (January 2007- June
2017). HRU and costs were measured over a 12-month period after TRD/non-TRD index date.
Counterfactual recycled predictions from multivariable generalized linear models were used to
examine associations between TRD and annual HRU and costs. Post-regression linear
decomposition identified differences in patient-level factors between TRD and no TRD group
that contributed to the excess economic burden of TRD.
Results: Of the 21,180 adults with CNPC and MDD, 10.1% were identified as having TRD.
TRD patients had significantly higher HRU, translating into higher average total costs
($21,015TRD vs $14,712No TRD) and MDD-related costs ($1,201TRD vs $471No TRD) compared to
non-TRD counterparts (all P <0.001). TRD patients had significantly higher number of inpatient
visits (IRR = 1.30. 95% CI = 1.14-1.47; P<0.001) than non-TRD patients. Overall, 46% of the
excess total costs were explained by differences in patient level characteristics such as
polypharmacy, number of CNPC, anxiety, sleep, and substance use disorders between the TRD
and no TRD groups.
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Conclusion: TRD poses a significant direct economic burden among adults with CNPC and
MDD. Excess healthcare costs may potentially be reduced by providing timely interventions for
several modifiable risk factors.
3.2 Introduction
Major Depressive Disorder (MDD) is a highly prevalent mental disorder and presents a
substantial economic burden.8,69 In 2015, the incremental economic burden of MDD in the
United States (US) was estimated to be as high as $210.5 billion, with $98.9 billion spent on
direct healthcare costs.8 Co-existence of MDD and chronic conditions has been reported to be the
main driver of this high economic burden.8 For example, MDD is associated with 50% to 100%
higher medical costs among patients with co-existing chronic conditions even after risk
adjustments.10 Among commonly co-occurring chronic conditions with MDD, chronic noncancer pain conditions (CNPC) is of particular interest because of the high prevalence and well
documented bi-directional relationship between MDD and pain.7,13,14 The prevalence of MDD in
patients with CNPC can be as high as 85%. 7 CNPC and MDD are inextricably linked in terms of
pain, biological pathways, and pathophysiology 14,15 which may contribute to the excess
economic burden of MDD. A study documenting the excess costs of MDD across 11 chronic
conditions including chronic non-cancer pain conditions (CNPC) such as osteoarthritis, joint
pain, back pain, and headache highlighted a substantial economic burden of MDD.102 A handful
of studies have also documented the excess economic burden of MDD among adults with CNPC,
47,103

which may be in part explained by the additive adverse effects of MDD and CNPC on

clinical outcomes.103,104
Additionally, the economic burden of MDD and CNPC may be amplified for patients
whose MDD is resistant to depression treatment. 11 It has been documented that patients with
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CNPC may not respond adequately to antidepressants, a major modality of depression treatment,
which can subsequently increase the risk of treatment-resistant depression (TRD).11 TRD is
primarily MDD in which patients do not achieve remission even after undergoing multiple
repeated and vigorous antidepressant treatment trials. 21,105 Studies have highlighted a high
prevalence of TRD among adults with CNPC.20,22,24,29 As adults with TRD tend to have much
longer episodes of depression, higher symptom severity, and higher healthcare resource
utilization (HRU), the association of TRD with high economic burden has been documented in
studies that are not specific to CNPC. 20,27,106 For example, adults with TRD had two times
higher direct healthcare costs and higher HRU as compared to adults without TRD. 25,41,42,44,46
However, to-date, no study has examined the economic burden of TRD among adults with
CNPC and MDD.
Estimating the economic burden of TRD in CNPC patients is important for several
reasons: 1) Many policy initiatives have shifted focus to the pursuit of triple aim of improving
the health of patients, quality of care and reducing healthcare costs,48 which requires
identification of high-cost, high-need patients;48 2) Payment reforms have focused on
reimbursement methods such as bundled payments for episodes of care which require risk
adjustment to account for differences in beneficiary-case mix. An up to date risk-adjusted
estimate of economic burden for those with MDD should also include excess costs due to TRD;
3) Helps in understanding their unmet needs, demonstrate the value for the need of targeted
interventions and increased investments in mental health resources in this population; and 4)
quantification of incremental burden of illness of TRD helps in translating the burden of illness
into dollar terms, the universal language for decision making.49
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Furthermore, TRD can be influenced by many factors.20,27,29,50 Therefore, it is important
to estimate how much of the excess economic burden can be explained by differences in patientlevel characteristics between those with TRD and non-TRD patients. Understanding factors that
can contribute the excess economic burden of TRD can aid payers in identifying major cost
drivers. Therefore, the main objectives of this study were: to estimate the excess economic
burden (direct healthcare utilization and costs) associated with TRD and to examine the extent to
which differences in patient factors between TRD and no TRD groups contribute to the excess
cost burden of TRD by using a post-regression linear decomposition approach among
commercially insured adults with CNPC and newly diagnosed MDD.
3.3 Methods
Data Source
This study was conducted using health insurance claims data (January 2007 through June
2017) from the de-identified Optum® Clinformatics® Data Mart. 67 We used the 10% random
sample of Optum data, which is a geographically diverse database, spanning across all 50 states.
It contains information on diagnoses, procedures, treatment, medication use, and costs derived
from inpatient, outpatient and pharmacy claims. Demographic characteristics (age, sex, state of
residence), and health plan information are also routinely collected during health insurance
enrollment. 67
Study Design
This study utilized a retrospective longitudinal cohort design. The study period consisted
of cohort identification, baseline, and follow-up periods. The cohort identification period was
used to identify adults with CNPC and newly diagnosed MDD. The baseline period, defined as
12 months before TRD index date (randomly imputed pseudo-index date for non-TRD) was used
to identify independent variables, including baseline HRU and costs. The follow-up period (12
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months after TRD index/pseudo-index date) was used to compute the economic outcomes (HRU
and direct costs).
Cohort Selection
The study cohort comprised adults with CNPC and newly diagnosed MDD (identified
using ICD9/10 codes) between January 2008 and June 2016 (Appendix 7.1). Adults with CNPC
were required to have at least two or more healthcare encounters during the cohort identification
period (i.e 12 months before the first observed MDD diagnosis). CNPC was identified using an
extensive list of conditions for which pain was severe enough to classify them as chronic pain
condition. 80-82 To ensure that the episode of MDD was newly diagnosed, we used a validated
algorithm of including only those who did not have any MDD diagnosis or antidepressant
prescription in 180 days prior to the MDD diagnosis date.78,79
We used the following additional inclusion-exclusion eligibility criteria to identify the
study cohort:1) adult patients (age > 18 years) with at least one antidepressant prescription
following MDD diagnosis, 2) no diagnosis for cancer throughout the study period, 3) consistent
with prior studies, those with a diagnosis of schizophrenia, schizoaffective disorder, other
psychosis, manic depression or bipolar disorders were excluded,22,23 4) continuous enrollment
during the 12 months before MDD identification and 24 months after MDD identification. (See
Figure 3.1 for number of individuals eliminated at each step of application of inclusion-exclusion
criteria). The final sample consisted of 21,180 adults with CNPC and newly diagnosed MDD.
Measures
Key Independent Variable: Treatment-Resistant Depression
We used a claims-based algorithm that was developed using the Massachusetts General
Hospital (MGH) clinical staging method. 23,61 This claims-based algorithm has been previously
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used to estimate the cost burden associated with TRD.23 Although previous studies using
administrative claims data to study TRD has defined TRD using different definitions,22,23,41,42 we
chose the MGH-based algorithm because it can be readily translated to prescription claims
information. Furthermore, it encompasses the four main strategies to overcome lack of
antidepressant treatment response, i.e. optimization, switching, combination, or augmentation. 62
We defined TRD using a point-based algorithm; one point was assigned for each adequate
antidepressant trial (i.e., 2 or more fills of the same antidepressant), and half a point for each
optimization strategy. The optimization strategies included extended duration (i.e. at least 3 fills
of the same antidepressant), an upward titration in dose, and augmentation with an atypical
antipsychotic, mood stabilizer, or thyroid hormone. Individuals exceeding three points were
considered to have TRD.23 Those using electroconvulsive therapy (ECT) were considered to
have TRD as ECT is often used as a late-stage treatment for TRD. 7
Study Outcomes
HRU and Direct Healthcare Costs
Direct costs and HRU (here-after referred as costs and HRU) included both all-cause
and MDD-related utilization and costs. For HRU, dependent variables were counts of total and
MDD-related inpatient admissions, outpatient visits, and emergency department (ED) visit.
Claims data from Optum are verified and adjusted with a standard pricing methodology to
account for variations in allowed payments across health plans and provider contracts prior to
inclusion in the Data Mart dataset. Total costs included allowed payments for inpatient stays,
facility outpatient visits, professional services, and prescription drugs from the insurer. Allowed
payments from the insurer were estimated and normalized to 2018 US dollars using the cost
factors and standardized prices provided by Optum Clinformatics ® DataMart. MDD-related
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costs and use were identified using the primary or secondary ICD-9/10 CM diagnosis codes
indicating MDD (see Appendix 7.1 for code definitions). Utilization and costs were summed
over a period of 12 months following TRD index/pseudo-index date
Other independent variables (measured at baseline)
The selection of other independent variables that could impact economic outcomes was
guided by the Modified Andersen’s Behavioral Framework of Health Services Use.64 The model
posits that the health services costs and utilization of an individual is primarily a function of
predisposing factors (e.g., age, sex), enabling factors (e.g. type of insurance plan, Medicare
advantage enrollment), need factors (e.g. chronic conditions, obesity, sleep disorders, tobacco
use disorder, and drug/alcohol use disorder, polypharmacy, benzodiazepine use, and use of pain
medication such as opioids and NSAIDs), and external environment (e.g. geographical region).
Chronic conditions included comorbid anxiety disorders, sum of CNPC conditions, and number
of chronic physical conditions other than CNPC. Baseline cost and resource use was also
measured.
Statistical Analyses
Baseline patient characteristics were compared between patients with and without TRD
using chi-square test for categorical variables and t-test for continuous variables. Adjusted
associations between TRD and HRU in the follow-up period was assessed using multivariable
negative binomial regressions and the results are reported using incidence rate ratios (IRR) and
95% confidence intervals (CI). The adjusted associations between TRD and healthcare costs
were evaluated using two-part models (TPM). Because healthcare and MDD-related costs had
zero mass (> 5%), we used two part models for all cost analyses107The first part of the model
used a logistic regression to assess the association between TRD and any positive cost and the
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second part of the model used generalized linear models (GLM) with a gamma distribution and
log-link function to handle positively skewed cost distribution. Rather than simply comparing the
expenditures between the groups for a reference case (i.e. marginal effects) robust estimates for
incremental costs between TRD and non-TRD groups were obtained using the counterfactual
recycled prediction technique from parameter estimates of GLM.108 Cost differences, p-values,
and their adjusted 95% confidence intervals were obtained from nonparametric bootstrap
procedures (500 replications). We present estimates from two models, one with risk-adjustment
for the predisposing, need, and external environmental factors described above and other with
additional risk adjustment for healthcare costs.
To estimate the extent to which differences in patient-level characteristics between TRD
and no- TRD groups contribute to the excess total costs associated with TRD, we use the
Blinder-Oaxaca linear decomposition approach.109,110,111 This technique assesses how much of
the difference in expenditures between the two groups may be due to observable or explained
factors (e.g. the predisposing, enabling, need, and external environmental factors described
above) versus unobservable or unexplained factors (e.g. lifestyle difference, social support,
education, income).The explained portion can be interpreted as counter-factual scenario (i.e.
estimated differences in cost burden if adults with TRD had the same characteristics as adults
without TRD). All data management and analyses were performed with SAS 9.4 (SAS Institute
Inc., Cary, NC) and Stata 14 (StataCorp LLC, College Station, TX).
3.4 Results
Sample Description
Of a total of 21,180 adults with CNPC and newly diagnosed MDD, 10.1% (N=2,147)
adults transitioned from MDD to TRD within one year of MDD diagnosis. On average patients
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identified as TRD were 53 years old and were predominately females (77%). The description of
study sample characteristics and subgroup differences in characteristics of adults with and
without TRD are presented in Table 3.1. Significant differences were observed in predisposing
and need factors between TRD and non-TRD groups. For example, a significantly higher
proportion of TRD patients had higher rates of polypharmacy (69.4% vs. 49.6%), had >3 CNPC
(40.6% vs. 32.1%), had comorbid anxiety disorders (55.7% vs. 15.3%), had sleep disorders
(33.6% vs. 23.7%), and drug/alcohol use disorders (15.9% vs. 8.1%) as compared to non-TRD
patients (all P <0.001). The rates of baseline HRU were significantly higher among adults with
TRD as compared to those without TRD (all P <0.001) (Table 3.1).
HRU
Unadjusted (Appendix 7.8) and adjusted rates (Figure 3.2) of HRU during the follow-up
period were higher for those with TRD as compared to those without TRD. Adults with TRD
had significantly higher number of inpatient (IRR = 1.30, 95% CI = 1.14 - 1.47) and ED visits
(IRR = 1.21, 95% CI = 1.10-1.34) and higher MDD-related healthcare utilization (e.g. 3.0 and
2.23 times the inpatient and ED visit rate) as compared to adults without TRD.
Healthcare Costs
We observed that the mean unadjusted total costs during the 12-month follow-up period
(Table 3.2) were higher for adults with TRD as compared to those without TRD ($21,015TRD and
$14,712No TRD), with an excess per patient cost of $6,303 (P <0.001). Prescription drug costs
accounted for 37.6%, inpatient services for 30.7%, outpatient services for 21.3% and ED use for
the remaining 10.6% of the excess TRD healthcare costs (can be calculated from Table 3.2).
Similarly, adults with TRD had significantly higher unadjusted MDD-related costs as compared
to adults without TRD ($1,201 vs. $471, P <0.001). Adults with TRD had significantly higher

48

costs for each component of all-cause and MDD-related costs as compared to adults without
TRD (Table 3.2).
Adjusted all-cause and MDD-related healthcare costs remained significantly higher
(Model 1) for those with TRD as compared to adults without TRD, yielding an excess cost
estimate of $3,388 for all-cause cost and $394 for MDD-related total costs. After additionally
adjusting for baseline healthcare costs (Model 2), the excess TRD costs reduced to $2,025 (allcause) and $296 (MDD-related). For all components of all-cause and MDD-related costs, those
with TRD had higher costs compared to those without TRD (P<0.001) (Table 3.2).
Table 3.3 summarizes the results from the post-regression linear decomposition. Nearly
half of the difference (46%) in total all-cause costs was explained by differences in the baseline
characteristics between the TRD and no TRD groups. This means that if the TRD group were to
have the same distribution of characteristics as the no-TRD group, 46% of the excess cost burden
can be reduced. Among all patient level factors, need factors, specifically differences in
polypharmacy rates contributed to over half (55.7%) of the explained portion of the total costs.
Other contributors to the excess cost burden were: number of CNPC (11.24%), tobacco and drug
use disorders (10.99%), and presence of sleep and anxiety disorders (8.17%). When baseline
costs were added to the model, it explained 65% of the difference in total healthcare costs
between the two groups (data not provided in tabular form).
Secondary Analysis
We also conducted a series of secondary analysis to ensure robustness of the association
between TRD and economic outcomes. First, we used inverse probability of treatment weighting
(IPTW) to account for observable selection bias between TRD and no TRD groups. 112 IPTWs
were derived from a multivariable logistic regression, in which presence or absence of TRD was
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the dependent variable. Second, we assessed the association between TRD and total all-cause
and MDD related healthcare costs over time. We captured costs during the observation period in
120-day periods over six intervals. In these models, polypharmacy (>5 concomitant use of
medications in a period of 90 days), use of benzodiazepines and use of pain –related medications
such as opioids and NSAIDs were measured in each of the 120-day periods. To account for
correlated errors terms due to repeated measures, we used generalized linear mixed model
(GLMM) with gamma distribution and log link.
IPTW adjustments (Appendix 7.7) and GLMM yielded results similar to the primary
analyses (Appendix 7.9). For example, GLMM analysis indicated that on average, patients who
transitioned to TRD had significantly higher all-cause total costs ($1746.5; β = 0.31; P value
<0.001) and MDD-related costs (β = 1.38; P value <0.001) at every time point in the baseline
and follow-up periods even after adjusting for patient characteristics (Appendix 7.9).
3.5 Discussion
Approximately one in 10 adults with CNPC and newly diagnosed MDD were identified
as having TRD, a finding consistent with some previously reported estimates of TRD from other
claims-based studies (6% to 15%).22,29,44,46 We observed that patients with TRD had
approximately 1.4 times higher total all-cause healthcare costs than adults without TRD.
Although, to date, no study has estimated excess economic burden of TRD among adults with
CNPC, we provide some comparisons based on studies that used similar algorithms to identify
TRD among in adults with MDD. Our adjusted total cost was similar to the estimates provided
by Gibson et al., who reported that TRD was associated with 40% higher total healthcare costs
among adults with MDD. 23 The findings from the current study were robust to the different
specifications of the models used in primary and sensitivity analysis. All models indicated
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significantly higher costs among adults with TRD compared to no TRD group. We observed a
higher economic burden among TRD patients at every 120-day period over two years. A
plausible reason may be the unremitting depressive state experienced by the TRD patients. Prior
research suggests that TRD patients had persistent depressive symptoms for nearly 61% of the
time over a three-year period.113 Therefore, our findings suggest that efforts in preventing
transition from MDD to TRD by screening patients for risk factors of TRD such as presence of
comorbid anxiety disorders, suicidal tendencies, hospitalization status, and high depression
symptom severity26,27,29 can potentially reduce costs of MDD among adults with CNPC and
newly diagnosed MDD.
In our study sample of adults with CNPC and newly diagnosed MDD, a significant
portion of the total all-cause costs was accounted by prescription drug costs, a finding consistent
with prior studies of TRD in commercially insured populations.22,42 We also observed that
polypharmacy rates from our study were significantly higher in the TRD group as compared to
no TRD group (69.4% vs 49.6%). Furthermore, results from the linear decomposition method
indicated that polypharmacy was a major driver of the excess total costs associated with TRD.
Our findings suggest that if adults with TRD were to have the same polypharmacy rates as adults
without TRD, the excess total cost burden associated with TRD as explained by all the
measurable baseline factors can be reduced by more than half (55.7%). Interventions that have
shown to reduce the risk of polypharmacy such as systematic review of high risk medications
(termed as "deprescribing"), medication therapy management, medication reconciliation, and
using a multidisciplinary care approach114 have the potential to off-set the excess costs due to
polypharmacy. Future studies on the cost of illness of TRD should use polypharmacy as a
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measure for risk-adjustment while presenting adjusted incremental cost estimates associated with
TRD.
Inpatient costs also accounted for a substantial share of all-cause as well as MDD-related
total healthcare costs. This is consistent with reports obtained from previous studies conducted
among adults with MDD. 22,25,42 The finding is also reflected by the significantly higher number
of all-cause (IRR=1.30) as well as MDD-related inpatient visits (IRR=3.00) among adults with
TRD as compared to those without TRD. A study by Crown et al. also reported that as compared
to the TRD patients treated in outpatient care, hospitalized TRD patients had significantly higher
MDD-related hospitalization as well as general medical costs.25Although, we did not explore the
reasons for all-cause or MDD-related hospitalizations, adults with TRD may have higher risk of
hospitalization and inpatient costs due to higher polypharmacy rates and greater occurrence of
chronic conditions such as number of CNPC, anxiety and substance use disorders as observed in
our study. It has been documented that polypharmacy can elevate risks of adverse drug–drug
interactions, which can lead to increased rates of hospitalizations and inpatient costs.115 TRD
patients may also engage in high-risk behavior such as substance use and suicidal attempts, at a
higher rate than no TRD patients,116,117which are all factors that increases the risk of
hospitalization and re-admissions.118,119
We also found that multimorbidity (example: number of CNPC, presence of anxiety,
sleep and substance use disorders) to be one of the major drivers of the excess total costs
associated with TRD. Research has shown that multimorbidity has a profound impact on
healthcare costs due to several reasons such as increased use of emergency department visits,
adverse drug events due to polypharmacy, and complex disease trajectories due to interactions
among chronic conditions.120 For example, adults with three or more CNPC may experience
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severe pain that may worsen clinical outcomes among adults with TRD.7 Co-management of
these commonly co-occurring conditions is often difficult, and results in higher healthcare
costs.121 Therefore, our findings suggests that the complex needs of patients with multimorbidity
can be better managed through healthcare delivery models that use collaborative and
multidisciplinary approaches. Such models have been shown to improve clinical outcomes, and
reduce costs as compared to the usual source of care.122,123 124
Strengths and Limitations
To date, this is the first real-world study to quantify the direct economic burden of TRD
among adults with CNPC and MDD; two very commonly co-occurring chronic conditions. The
longitudinal study design with repeated measures allowed for an assessment of baseline as well
as follow-up profiles in terms of utilization, expenditures as well as baseline patient
characteristics. Further, MGH scoring algorithm to identify TRD allows for a nuanced and
comprehensive assessment of TRD by accounting for number of failed adequate trials, treatment
dose, titration, duration and augmentation. Additionally, the current study ensured robustness of
study findings by adjusting for observed selection bias through IPTWs and by employing the use
of counterfactual-recycled predictions in addition to the use of a two-part GLM model. This
allowed us to obtain estimates for an average patient as compared to estimates obtained from a
reference-case scenario using marginal effects derived from the two-part GLM regression
models.
Although the insights from the current study are important, the limitations of the current
study need to be considered while interpreting the study findings. TRD was defined using
pharmacy claims and ECT use and excludes other clinical considerations such as type of
symptoms, responsiveness to medical treatments, and tolerance to antidepressants. Further, we
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may not have truly captured the actual use of medication as we could observe only presence of
prescription claims. It is also plausible that by limiting patients to only MDD diagnosis, we may
have underestimated the prevalence of MDD because MDD may at times could be recorded with
general depression code. As shown from the results of the decomposition analysis, absence of
information on factors such as severity of MDD and pain, socioeconomic status, race/ethnicity,
physical activity, and social support could contribute to the unexplained portion of the total costs
differences between adults with and without TRD, which could impact the study findings. Our
study estimated costs from a third-party payer perspective, therefore; indirect costs such as costs
related to traveling, caregiving and loss of productivity have not been considered. In estimating
costs associated with MDD, costs of prescription medications have not been considered as
medications such as antidepressants and atypical antipsychotics were used in the algorithm to
identify patients with TRD and these medications could also be used for other physical
conditions such as pain, and insomnia. 125 Finally, although our study was not limited to
including only working-aged adults, our results may not be generalizable to other privately and
publicly insured adults. Additionally, no direct inference should be made about the prevalence of
TRD based on the size of the analytical sample which was selected based on several
inclusion/exclusion criteria.
3.6 Conclusion
This is the first study to document the excess direct economic burden of TRD among
adults with CNPC and newly diagnosed MDD. TRD in adults with CNPC and newly diagnosed
MDD was associated with substantial all-cause and MDD–related costs and HRU. Estimates
from our study can provide a benchmark of TRD costs for future cost-effectiveness studies and
in estimating risk-adjusted cost for value-based reimbursement initiatives. Potential cost savings
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associated with managing TRD may stem from reducing the risk of polypharmacy, better comanagement of chronic pain and co-occurring substance use, anxiety, and sleep disorders.
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Figure 3.1. Schematic presentation of study sample selection
Patients with MDD in years 2008-2016
N=683,701

Patients who are cancer free and have >2 diagnosis of any
CNPC in 12 months before MDD
N=201,955
)

Patients without schizophrenia, schizoaffective disorders,
other psychosis, manic depression or bipolar disorder
N=192,328

Patients with newly diagnosed MDD (No MDD diagnosis
or antidepressant prescription in prior 180 days)
N=90,937

Patients receiving antidepressant treatment (>1
antidepressant fill after MDD diagnosis)
N=50,664

Final analytical sample: Patients aged >18 years with
continuous enrollment up to 24 months before and 12
months after the TRD index date
N=21,180

Patients classified with
TRD
N=2,147 (10.1%)

Patients not meeting the
definition of TRD
N=19,033 (89.9%)
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Table 3.1. Baseline Characteristics of Adults with CNPC and Newly Diagnosed MDD

Characteristics

Optum Clinformatics Real-World De-identified Data, 2007-2017
Patients classified
Patients without
Overall (N=21,180)
with TRD
TRD (N=19,033)
(N=2,147)
N
%
N
%
N
%
Predisposing factors

Age, Mean (SD)
Female

55.18 (17.60)
15,610

53.25 (16.62)
73.7

1,654

77.0

55.84 (17.69)
13,956

73.3

Age group
18-34 years

2,781

13.1

293

13.6

2,488

13.1

35-44 years

3,119

14.7

360

16.8

2,759

14.5

45-54 years

4,190

19.8

497

23.1

3,693

19.4

55-64 years

4,087

19.3

448

20.9

3,639

19.1

>65 years

7,003

33.1

549

25.6

6,454

33.9

P value

Sig

<0.001

***

<0.001

***

<0.001

***

Enabling factors
Medicare Advantage Enrollment
Commercial
Medicare Advantage

0.106
12,470

58.9

1,299

60.5

11,171

58.7

8,710

41.1

848

39.5

7,862

41.3

Insurance plan type
HMO
PPO/POS
Other

0.269
7,439

32.1

661

30.8

6,129

32.2

11,317

46.9

1,042

48.5

8,899

46.8

4,889

21.0

444

20.7

4,005

21.0

Need Factors
No. of CNPC

a

<0.001

1

4,823

22.8

402

18.7

4,421

23.2

2

9,430

44.5

873

40.7

8,557

45.0

>3

6,927

32.7

872

40.6

6,055

31.8

b

***

Number of physical chronic conditions
0
7,925

37.4

808

37.6

7,117

37.4

1 to 2

7,620

36.0

777

36.2

6,843

36.0

>3
Anxiety disorders

5,635

26.6

562

26.2

5,073

26.7

8,057

38.0

1,195

55.7

6,862

36.1

<0.001

***

Sleep disorders

5,227

24.7

722

33.6

4,505

23.7

<0.001

***

Tobacco use disorders

2,428

11.5

320

14.9

2,108

11.1

<0.001

***

Drug/alcohol use disorder

1,892

8.9

342

15.9

1,550

8.1

<0.001

***

Obesity diagnosis

3,487

16.5

383

17.8

3,104

16.3

0.07

Polypharmacy
Yes
No

0.893

c

<0.001
10,926

51.6

1,490

69.4

9,436

49.6

10,254

48.4

657

30.6

9,597

50.4

57

***

Commonly used medications c
NSAIDs

5,328

25.2

601

28.0

4,727

24.8

0.001

**

Opioids

7,285

34.4

792

36.9

6,493

34.1

0.01

*

Benzodiazepines

6,542

30.9

928

43.2

5,614

29.5

<0.001

***

5.23

0.156

Environmental factor
Census region of residence
Northeast

1,910

9.0

217

10.1

1,693

8.9

Midwest

5,154

24.3

535

24.9

4,619

24.3

South

8,610

40.7

866

40.3

7,744

40.7

West

5,506

26.0
529
24.6
Bassline costs and resource use e

4,977

26.1

Baseline visit to provider
Primary Care provider

16,063

75.8

1,930

89.9

14,133

74.3

<0.001

***

Mental health specialist

4,872

23.0

1,046

48.7

3,826

20.1

<0.001

***

Inpatient

4,468

21.1

648

30.2

3,820

20.1

<0.001

***

ED

7,938

37.5

987

46.0

6,951

36.5

<0.001

***

15,637

73.8

1,702

79.3

13,935

73.2

<0.001

***

1,443

6.8

318

14.8

78

5.9

<0.001

***

Inpatient

687

3.2

182

8.5

505

2.7

<0.001

***

ED

544

2.6

131

6.1

413

2.2

<0.001

***
***

All-cause healthcare visits (>1)

Outpatient
MDD- related healthcare visits (>1)
Outpatient

All-cause healthcare costs (2018 US$), Mean (SD)
Total costs

17,287 (42,843)

MDD-related healthcare costs (2018 US$), Mean (SD)
Total MDD related medical
costs
916 (7,079)

23,138 (39,632)

16,627 (43,141)

<0.001

1,772 (8,125)

818 (6,944)

<0.001

***

Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain conditions, HMO:
Health Maintenance Organization, PPO: Preferred provider organization, POS: Point of service, other plan type includes fee-for-service,
indemnity plans, EPO (exclusive provider organization), GPO (Group purchasing organization), IPP(individual program plan), and other
plans, NSAIDs: Non-steroidal anti-inflammatory drugs, SD: Standard deviation. ED: emergency department, Sig: Significance
Note: Based on 21,180 adults with CNPC and newly diagnosed MDD receiving antidepressant medication treatment who were continuously
enrolled during the observation period. All baseline factors were measured in the 12-month period before the index date. The first TRD date
was used as the index date for patients classified as having TRD and for those classified as non-TRD patients, a pseudo index date was
randomly selected based on the TRD index date.
a Number of CNPC conditions were obtained as sum of common chronic painful conditions such as back/neck pain, headache/migraine,
arthritis/joint pain, and neuropathic pain/other chronic pain conditions.
b Physical chronic conditions examined included conditions other than CNPC conditions such as asthma, coronary artery disease, cardiac
arrhythmias, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, hypertension, hyperlipidemia,
osteoporosis, and stroke.
c Polypharmacy was defined as concomitant use of five or more medications within a 90 day period before the index date.
e Total all-cause healthcare costs included the standardized costs for all healthcare medical and pharmacy services paid by payers, including
those for outpatient visits, inpatient stays, ED visits, and prescription medications. Total MDD-related medical costs included costs for
medical- related services including inpatient visits, outpatient and ED visits.
*** p < 0.001.; ** .001 ≤ p < .01; * .01 ≤ p < .05
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Table 3.2. Mean Annual Adjusted and Unadjusted All-Cause and MDD-Related Costs
Among Adults with CNPC and Newly Diagnosed MDD by TRD status
Optum Clinformatics DataMart, 2007-2017

Outcomes

Patients
classified
withTRD

Patients
without
TRD

Unadjusted
Incremental costs

Adjusted Incremental
costs, Model 1 a

Adjusted Incremental
Costs,Model 2 b

Unadjusted
Mean (SD),
$

Unadjuste
d Mean
(SD), $

Mean $
(95% CI); P value

Mean $
(95% CI); P value

Mean $
(95% CI); P value

6303
(4,396 - 8,209); <0.001

3,388
(3,353-3,419); <0.001

2,025
(2,015 - 2,056); <0.001

All-cause healthcare costs (2018 US$)
Total
21,015
14,712
(42,504)
(42,746)
Prescription
drug costs
Inpatient

6,286
(10,014)
7,603
(34,608)

3,913
(9,050)
5,667
(34,969)

2373
(1,964 - 2,781); <0.001
1,936
(377 - 3,495); 0.014

1,281
(1,370-1,293); <0.001
1,329
(1,313 - 1,346); 0.012

776
(768 - 785); <0.001
894
(883 - 907); 0.108

5,338
(14,972)
ED
1,789
(5,100)
MDD-related healthcare
costs (2018 US$)
Total
1,201
(5853)
Inpatient
543
(4557)
Outpatient
470
(2,980)
ED
188
(1,178)

3,998
(17,545)
1,135
(3,922)

1,340
(567 - 2,112) ;<0.001
654
(473 - 835); <0.001

764
(758 - 770); 0.008
223
(221 - 225); 0.002

662
( 656 - 668); 0.004
174
(172 - 175); 0.011

471
(3771)
169
(2890)
213
(1,843)
89
(869)

730
(550 - 909); <0.001
374
(236 - 513); <0.001
257
(168 - 346); <0.001
99
(57 - 138); <0.001

394
(389 - 399); <0.001
276
(272 - 280); <0.001
84
(92 - 85); <0.001
14
(13-15); 0.001

296
(291 - 301); <0.001
228
(224 - 231); <0.001
61
(60 - 62); <.001
12
(11-13); 0.004

Outpatient

Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain conditions,
SD: Standard deviation; ED: Emergency Department
Note: The sample includes all eligible adults with CNPC and newly diagnosed MDD who are treated with antidepressants and were
continuously enrolled throughout the study observation period (N=21,180) from the de-identified Optum Clinformatics DataMart.
All the costs were standardized to 2018 US dollar. Total all-cause healthcare costs included the standardized costs for all healthcare
medical and pharmacy services paid by payers, including those for outpatient visits, inpatient stays, ED visits, and prescription
medications. Total MDD-related medical costs included costs for medical- related services including inpatient visits, outpatient and ED
visits. Total MDD-related costs were identified based on primary/secondary diagnoses of MDD.
Unadjusted incremental costs and their corresponding P value and 95% CIs have been obtained using ordinary least square regressions.
a Incremental costs from Model 1 were measured using counterfactual recycled predictions performed using estimates obtained from a
2-part GLM model with log link and gamma distribution which adjusted for baseline factors: predisposing factors (age, sex), enabling
factors (Medicare Advantage enrollment, type of insurance plan), need based factors (number of physical chronic conditions, number of
CNPC, presence of anxiety disorders, sleep disorders, obesity, and baseline medication use (polypharmacy, NSAIDs, opioid and
benzodiazepine use), and environmental factors (region).
b Incremental costs from Model 2 were measured using counterfactual recycled predictions performed using estimates obtained from a 2part GLM model with log link and gamma distribution which adjusted for all baseline factors mentioned in model 1 and healthcare costs.
a,b All P values and their confidence intervals were obtained using nonparametric bootstrap procedure (N=500) on the predicted values
obtained from recycled predictions.
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Figure 3.2. Adjusted average annual healthcare resource utilization associated with TRD
among adults with CNPC and newly diagnosed MDD

Note: All healthcare resource utilization was measured from the index date up to 12 months after the index date. The sample
includes all eligible adults with CNPC and newly diagnosed MDD who are treated with antidepressants and were continuously
enrolled throughout the study observation period (N=21,180) from the de-identified Optum Clinformatics DataMart.
Adjusted IRRs and their corresponding P values were obtained using a generalized linear model (GLM) with a negative binomial
distribution (based on the results of the over dispersion test). The model adjusted for baseline predisposing factors (age, sex),
enabling factors (Medicare Advantage enrollment, type of insurance plan), need based factors (number of physical chronic
conditions, number of CNPC, presence of anxiety disorders, sleep disorders, obesity, and baseline medication use
(polypharmacy, NSAIDs, opioid and benzodiazepine use), environmental factor (region), and baseline healthcare utilization.
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain
conditions, SD: Standard deviation; ED: Emergency Department, IRR: Incidence Rate Ratio
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Table 3.3. Post Linear Decomposition to Explain Contribution of Patient Factors on All-Cause Total
Healthcare Cost: Differences by TRD Status
Among Adults with CNPC and Newly Diagnosed MDD
Optum Clinformatics DataMart, 2007-2017
Explained Differences in Average Log-transformed All-Cause Total Healthcare Costs
Pooled
Explained
SE; P Value
%
Characteristics
(β)
difference d
Predisposing factors
Age, Sex
0.0127
0.0045; 0.006
3.78%
Enabling factors
Insurance plan type, Medicare Advantage Enrollment
0.0003
0.0033; 0.938
0.08%
Need factors
No. of CNPC a
0.0377
0.0051; <0.001
11.24%
Anxiety disorders, sleep disorders
Tobacco use disorders. Drug/alcohol use disorder
No. of physical chronic conditions b, Obesity diagnosis
Polypharmacy
Commonly used medications: NSAIDs use, Opioid
use, Benzodiazepine use
External environment
Region
Total explained

0.0274
0.0369

0.0058; <0.001
0.0052; <0.001

8.17%
10.99%

-0.0021

0.0074; 0.779

-0.63%

0.1870

0.0113; <0.001

55.73%

0.0171

0.0045; <0.001

5.09%

0.02
0.34

0.0048; <0.001

5.53%
46.02%

Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain conditions,
SE: Standard Error
Note: The sample includes all eligible adults with CNPC and newly diagnosed MDD who are treated with antidepressants and were
continuously enrolled throughout the study observation period (N=21,180) from the de-identified Optum Clinformatics DataMart.
a Number of CNPC conditions were obtained as sum of common chronic painful conditions such as back/neck pain,
headache/migraine, arthritis/joint pain, and neuropathic pain/other chronic pain conditions.
b Physical chronic conditions examined included conditions other than CNPC conditions such as asthma, coronary artery disease,
cardiac arrhythmias, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, hypertension,
hyperlipidemia, osteoporosis, and stroke.
c Polypharmacy was defined as concomitant use of five or more medications within a 90-day period before the index date.
All the costs were standardized to 2018 US dollar. Total all-cause healthcare costs included the standardized costs for all healthcare
medical and pharmacy services paid by payers, including those for outpatient visits, inpatient stays, ED visits, and prescription
medications.
The post linear decomposition is based on pooled weights. The pooled weights were derived from parameter estimates of ordinary least
square regression (OLS).
Average log-transformed total healthcare expenditures for adults with TRD was 8.93 and for adults without TRD was 8.20, yielding a
difference of 0.73
Column d gives the percentage of the difference in total all-cause expenditures by TRD as explained by differences in each independent
variable domain between the two groups
Explained portions of no. of physical health conditions/obesity diagnosis had negative signs. These negative signs suggest that keeping
other factors constant, if the "TRD" group had the same distribution of characteristics as the "no TRD" group; no. of physical health
conditions/obesity diagnosis), the all-cause total healthcare expenditures of individuals with TRD would be higher.
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CHAPTER 4
4 Trajectories of Long-term Opioid Use: The Role of Treatment-Resistant Depression
among Adults with Chronic Non-Cancer Pain Conditions and Newly Diagnosed Major
Depressive Disorder
4.1 Abstract
Background: Although treatment guidelines discourage long-term opioid therapy (LTOT) for
patients with co-existing chronic non-cancer pain conditions (CNPC) and major depressive
disorder (MDD), many patients receive LTOT in real–world practice settings. Further, treatmentresistant depression (TRD) may increase the risk of LTOT. We examined the trajectory of LTOT
use before and after MDD diagnosis and the association of TRD with LTOT among patients with
CNPC and newly diagnosed MDD.
Methods: Retrospective, longitudinal analysis of patients with CNPC and newly diagnosed
MDD (N=21,599) using de-identified data from commercially insured adults (January 2007-June
2017) was conducted. TRD was identified using a claims-based algorithm and LTOT (defined as
>90 consecutive days) of prescription opioids was measured every 180 days over a 3-year period
anchored to the date of MDD diagnosis. The adjusted relationship between TRD and LTOT was
examined using generalized estimating equation models.
Results: In our study sample, 11.8% of adults with CNPC transitioned from MDD to TRD.
During the study period, LTOT use declined from 15.6% in time 1 to 10.3% in time 6 (P < .001).
Adults identified with TRD were more likely to receive LTOT, as compared to those without
TRD [adjusted odds ratio (AOR): 1.54, 95% CI: 1.68-2.04). However, LTOT in this group
declined over time at a higher rate, than those without TRD (β= -.033, SE=0.012).
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Conclusion: Adults with TRD were more likely to receive LTOT at every time period over a 3year period than those without TRD, although LTOT use declined over time. Close monitoring
of the risks of using LTOT among adults with CNPC and TRD is warranted.
4.2 Introduction
Given that many patients with chronic non-cancer pain conditions CNPC suffer from
persistent pain, they often receive long-term opioid therapy (LTOT),81,126 commonly defined as
continuous use of opioid beyond 90 days. 126-128 Use of LTOT in patients with CNPC is
controversial, 33,34,53,129-131 with some believing that it may improve pain outcomes,132 while
others warning that the evidence is limited regarding the effectiveness of LTOT for different
types of chronic pain such as neuropathic, nociceptive, and mixed pain types.133,134 Furthermore,
LTOT often increases the risk of adverse events such as constipation, nausea, addiction, and
opioid-induced hyperalgesia.134,135
In fact, clinical guidelines do not recommend use of LTOT among specific subgroups of
patients, specifically those with co-occurring CNPC and major depressive disorder (MDD). 55
Prevalence rates of MDD range from 28% in population-based research to as high as 89% in
orthopedic clinics.17, 18 Prospective studies have reported that MDD makes chronic pain less
responsive to opioids among adults with CNPC,55,136 further limiting the clinical benefits of
LTOT in this subgroup. Despite lack of robust evidence on the long-term efficacy of opioids,
many patients with CNPC and MDD receive LTOT in real-world practice settings. It has been
reported that adults with MDD and CNPC are more likely to receive LTOT, as compared to
those without MDD.56 Because pain is also a somatic symptom of depression, MDD can make
chronic pain worse in adults with CNPC. This may lead to opioid prescribing at a much higher
rate and longer duration among those with CNPC and MDD, than in patients who have CNPC
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without MDD.60,137,138 As MDD is harder to treat with antidepressants in the presence of chronic
pain,11 LTOT may be prescribed at a higher rate for pain control to patients who do not respond
to multiple antidepressant trials.55 Patients with MDD and co-occurring CNPC have a higher risk
of developing treatment-resistant depression (TRD),20,22,24,29 commonly defined as failing
multiple trials of antidepressants.17-20 TRD may increase the use of LTOT55 as the neural
patterns of activation that are associated with depression are also associated with pain, and
LTOT may be prescribed to treat the complex combination of both pain and TRD.55,57
On the other hand, clinicians may be cautious in prescribing LTOT to patients with MDD
who develop TRD because these patients may also have higher rates of substance use disorders,
including opioid-use disorders.55,139 Therefore, it is plausible that LTOT use before and after
MDD diagnosis may vary, and TRD may alter this trajectory. To date, no study has examined the
trajectory of LTOT among adults with CNPC and newly diagnosed MDD, or the association of
TRD with LTOT. TRD is now receiving increased attention because of its high clinical,
economic and societal burden.20 The only retrospective study in the US that examined the
relationship between TRD and LTOT focused on Veterans, and reported that LTOT is a risk
factor for TRD. The study did not report on the association of TRD with LTOT.30
An understanding of the relationship between LTOT and TRD is important for several
reasons. First, LTOT among adults with TRD may be deemed to be “high-risk” as both LTOT
and TRD are independently associated with increased risk of substance use disorders,54,139 and
adverse health outcomes20,22 Second, patients with TRD receiving LTOT comprise a patient
population where the benefits of LTOT are questionable and vulnerability to risks of adverse
events related to LTOT are very high; making it critical for healthcare providers to weigh the
risks versus benefits of using LTOT in this group of patients. Furthermore, having an
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understanding of LTOT prescribing patterns among individuals with CNPC and newly diagnosed
MDD is important to better inform clinical practice, payers, and policy makers in their
surveillance and prevention efforts of controlling opioid- related misuse and abuse. To fill the
existing knowledge gap and provide further insights on the real-world pattern of LTOT use, the
current study sought to examine the trajectory of LTOT over a 3-year period in adults with
CNCP and the association of TRD with LTOT among adults with CNPC and newly diagnosed
MDD.
4.3 Methods
Data Source
The study used health claims from the de-identified 10% sample drawn from the Optum
Clinformatics ® DataMart (Optum Clinformatics ®, Eden Prairie, MN, USA) 67 from 1st January
2007 through 30th June 2017. This geographically diverse database contains information on
prescription drug claims [e.g. generic drug names, days’ supply, prescription fill dates], medical
claims (e.g. International Classification of Diseases, ninth/tenth revision [ICD-9/10] diagnoses,
Current Procedural Terminology codes], and eligibility information [e.g. age, sex].67
Study Design
We adopted a retrospective, observational, longitudinal cohort design, with repeated
measurements of LTOT every 180-days for six time points (T1, T2, T3, T4, T5, and T6) over a
3-year observation period. Repeated measurements were anchored to the date of newly
diagnosed MDD with pre-index (T1, T2) and post-index periods (T3, T4, T5, and T6). To allow
sufficient time for follow-up newly diagnosed MDD was restricted to the period between
January 1, 2008 to June 30, 2015. To ensure that the episode of MDD was newly diagnosed
episode, we used a validated algorithm of including only those who did not have any MDD
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diagnosis or antidepressant prescription in 180 days prior to the MDD diagnosis date.78,79 A 12month pre-index period was used for cohort identification and TRD was identified in the
subsequent 12-month post-index period (T4 and T5) (Figure 4.1).
Study Cohort
The study cohort comprised commercially insured adults with CNPC and newly
diagnosed MDD identified using ICD-9 codes (see Appendix 7.1 for classification codes). Adults
with CNPC were required to have at least two healthcare encounters during the pre-index period.
Chronic non-cancer pain conditions, identified using an extensive list of conditions for which
pain was severe enough to call them as chronic pain conditions,80-82 was grouped into four broad
categories encompassing the most common pain conditions (back/neck pain, headache/migraine,
arthritis/joint pain, neuropathic/other chronic pain).127,140 Other inclusion/exclusion criteria were
age > 18 years, at least one prescription of antidepressant following MDD diagnosis, no cancer
diagnosis, and continuous enrollment throughout the study observation period. Additionally,
similar to prior studies we excluded patients with any diagnosis of schizophrenia, schizoaffective
disorder, other psychosis, manic depression or bipolar disorders.22,23 After applying the
inclusion/ exclusion criteria, the final study sample consisted of 21,599 adults (Figure 4.2).
Measures
Key Independent Variable: Treatment Resistant Depression
Due to a lack of consensus on the definition of TRD, there are inconsistencies in the
measures/algorithms used to identify TRD from a claims database.72,141,142 For the current study,
adults with TRD were identified using a comprehensive claims-based staging algorithm that was
developed using the General Hospital (MGH) clinical staging method. 23,61 As per this algorithm,
a patient with CNPC and MDD was classified as meeting the criteria for TRD if his/her MGH
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score exceeded three points. Patients were scored as follows: 1) one point was assigned for each
adequate antidepressant trial (i.e., 2 or more fills of the same antidepressant); 2) half a point was
assigned for each optimization strategy (included extended duration, i.e. at least 3 fills of the
same antidepressant, an upward titration in dose, and augmentation with an atypical
antipsychotic, mood stabilizer, thyroid hormone;233) Four points for patients using
electroconvulsive therapy (i.e. those using ECT were directly considered to have TRD as ECT is
often used for late-stage treatment for TRD.7(See Appendix 7.10 for the list of augmentation
medications and the number of patients meeting each of the MGH scoring criteria).
Outcome: Long-term opioid therapy (LTOT)
Opioids were identified using the therapeutic drug classification for opiate agonists
(codeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, morphine,
oxycodone, oxymorphone, and pentazocine) from the dataset.30 Following the algorithms used
in published literature, LTOT was defined as receiving greater than 90 days’ supply of opioids
with less than a 30-day gap between two fills within a 180-day period.30,127,128,140,143 A threshold
of >90 days was chosen because it corresponds to usually 4 or more prescriptions and it is
unlikely for an individual to receive opioids for >90 days for acute pain conditions. Additionally,
this threshold represents an important point in the treatment process where clinicians would want
to be cautious of the clinical risk of continuing opioid treatment, thereby making it a reasonable
threshold for risk analysis.128,140 We explored the effect of TRD on LTOT using a sensitivity
analysis by defining LTOT using a 120-day period of continuous opioid supply with a 30-day
permissible gap.56 In the current study, we used LTOT as defined by duration of opioid use as
our outcome variable and not dose of opioids because previous studies have highlighted that new
onset of MDD and TRD is associated with longer duration of opioids and not dose.30,137,144
Other Independent Variables
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Selection of other explanatory variables (time invariant and time-varying) was guided by the
expanded Symptom Management Model.65,66 As per the proposed framework, presence of TRD,
which is mainly non-response to antidepressant treatment trials, was considered as a symptom
experience which can influence the outcome of LTOT. As per the model, the above dimensions
can be influenced by the following three domains: (1) the personal domain, which comprised of
demographic and socio-economic factors (e.g. age, sex, insurance plan type, Medicare advantage
enrollment), (2) the health and illness domain (e.g. chronic physical conditions, obesity, sleep
disorders, substance use disorders, polypharmacy, benzodiazepine use, and use of pain
medication such as NSAIDs); (3) the environmental domain (e.g. geographical region, index
year). Our study included both time varying and time invariant factors. Substance-use disorders,
polypharmacy, NSAIDs and benzodiazepine use were measured during each time interval from
T1 to T6. All other variables were measured during the baseline (pre-index period).
Statistical Analyses
Differences in baseline sample characteristics among adults by LTOT status in the preindex period and TRD status in the post-index period (T4 and T5) were compared using chisquare tests for categorical variables and t-tests for continuous variables (e.g. age). Considering
that LTOT was measured repeatedly every 180-days during the pre- and post-index period, with
each individual having six observations, these six observations were not independent. As
standard regression techniques cannot be applied to correlated observations, we used unadjusted
and adjusted generalized estimating equations (GEE).145 The GEE accounts for correlated error
terms due to repeated measures from the same individual and is fairly robust to choice of
correlation matrix, particularly with large sample sizes. In the current study, population-averaged
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GEE with binary distribution was used. A population averaged model provides group effect, in
contrast to subject-specific model which includes a ‘unique’ effect for each individual.146
We also analyzed the interaction between TRD and time to elucidate the impact of TRD
on the trajectory of use of LTOT over time. Unadjusted and adjusted Odds Ratios and their
corresponding 95% confidence intervals have been reported. The adjusted GEE model controlled
for time, personal, health and illness, and environmental factors. All data management and
analyses were performed with SAS 9.4 (SAS Institute Inc., Cary, NC) and Stata 14 (StataCorp
LLC, College Station, TX).
4.4 Results
Sample Characteristics
Among 21,599 adults with CNPC and newly diagnosed MDD, 2550 (11.80%) met the
criteria for TRD within one year of MDD diagnosis, with a mean time of 8 months. Adults with
CNPC and newly diagnosed MDD were mostly females (73.6%) with a mean age of 55.2 years.
The majority of adults in our study had arthritis/joint pain (91%), followed by back/neck pain
(71%). About 16% of adults were on LTOT during the pre-index (baseline) period. (Table 4.1).
Sample Characteristics by TRD
TRD patients were mostly younger with a mean age of 53.7 years, as compared to those
without TRD (mean age=55.43 years). There were significant differences in personal factors and
health and illness –related factors between adults with and without TRD. For example, a greater
percentage of adults with TRD had >3 CNPC (41.4% vs. 32.2%), had co-existing sleep disorders
(29.9% vs. 22.0%), anxiety disorders (36.9% vs. 26.5%), and used polypharmacy (59.1% vs.
43.4%), as compared to CNPC patients without TRD (all P<.001) (Appendix 7.11).
Sample Characteristics by use of LTOT
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The baseline sample characteristics among those using LTOT and not using LTOT in the
pre-index period differed significantly across all domains, including personal, environmental,
and health and illness factors (All P <0.01) (Table 4.1). For example, a higher percentage of
adults on LTOT were males (28.3 % vs. 16.1%), had >3 CNPC (58.5% vs. 28.2%), and had >3
physical chronic conditions (35.0% vs. 26.3%).
Trajectory of LTOT over 3-year study period
In our sample, LTOT use declined from 15.7% in T1 to 10.3% in T6 and the decline was
significant (Figure 4.3). In unadjusted GEE models, when time was included as the only
covariate, the time co-efficient was found to be negative ( = -.055, SE=.003), suggesting that
LTOT use decreased over time. For example, LTOT use was less likely at T6 (OR = 0.76, 95%
CI= 0.73- 0.79), compared to the pre-index (T2) period (Table 4.2). When examined by TRD
status, a significantly higher percentage of adults with TRD used LTOT (P < .001) as compared
to non-TRD patients at all time-points (Figure 4.3). Those with TRD were more likely to receive
LTOT (OR = 1.76; 95% CI = 1.62-1.91), after adjustment for time. Over time, the difference in
LTOT rates among TRD and non-TRD patients narrowed (T1: 9.7 percentage point difference;
T6: 5.0 percentage point difference). The interaction term between time and TRD status was
negative ( -.022, SE= .01), suggesting that TRD patients had a greater decline in LTOT,
compared to non-TRD patients (Table 4.2).
In fully-adjusted models (after adjusting for TRD, time-interaction with TRD, personal,
environmental, and health and illness factors), adults with TRD were 1.5 times as likely to use
LTOT, as compared to adults without TRD (AOR=1.55, 95% CI=1.39-1.71, P value <0.001).
The interaction term between time and TRD status remained negative ( -.033, SE=0.012) and
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statistically significant (P Value = 0.006). The sensitivity analyses, where LTOT was defined as
>120 days’ supply of opioids, showed similar results (Appendix 7.12 and 7.13).
Other factors associated with LTOT included: male sex, younger age (35-64 years),
greater number of CNPC and physical chronic health conditions, comorbid anxiety disorders,
polypharmacy, any use of NSAIDs, and benzodiazepines (Table 4.2). Furthermore, adults
diagnosed with MDD in years after 2010, had lower odds of LTOT use, as compared to those
diagnosed in years 2008-2010 (years 2011-2013: AOR: 0.86, 95% CI: 0.79-0.94; years 20142015: AOR: 0.66, 95% CI: 0.61-0.72).
4.5 Discussion
To the best of our knowledge, this is the first real-world study that examined the
trajectory of LTOT among adults with CNPC and newly-diagnosed MDD, and the association of
TRD with LTOT. We found an average LTOT rate of 16% , which is in line with a previous
study that reported a prevalence of 12% to 30% LTOT use among adults with CNPC and mood
disorders.140 Overall, we found that adults who transitioned from MDD to TRD were
significantly more likely to receive LTOT, as compared to adults who did not transition to TRD.
This difference remained statistically significant at all time points. Even after adjusting for time
and other patient factors, adults with TRD were more likely to receive LTOT (AOR=1.54, P
value <0.001), compared to those without TRD. Although it was not possible to ascertain
reasons for higher LTOT use among TRD patients, there are some possible explanations based
on what is known about TRD and chronic pain. It is well known that adults with TRD report
greater severity of depression, physical symptoms, higher levels of pain, and a higher number of
CNPC, as compared to those with MDD without TRD. 22,24,26 11,147 It is plausible that those with
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TRD have more severe pain which may not be responsive to first line pain therapies and opioids
may be prescribed to these patients to treat an undifferentiated state of mental and physical pain.
While TRD is associated with LTOT, we cannot rule out the possibility that LTOT may
worsen depression symptoms over time,55 which may lead to TRD.30 In fact, to date, only one
retrospective cohort study in the United States (US) has reported increased risk of new onset
TRD due to longer duration of opioid use among Veterans.30 A recent study has also reported
that mu opioid receptor agonists may worsen depression symptoms thereby increasing the risk of
TRD.30 On the other hand, emerging evidence from clinical trials suggests that antagonists of the
kappa opioid receptor, such as buprenorphine, may improve depression symptoms, 148,149
reducing the risk of TRD.149 Therefore, future real-world studies are needed to explore the
bidirectional relationships between LTOT and TRD, and the role of antagonists of the kappa
opioid receptors for managing both pain and TRD.
A noteworthy finding was the general decline in LTOT over the 3-year observation
period among CNPC patients newly diagnosed with MDD in recent years. Additionally, adults
diagnosed with MDD in recent years (2011-2015) were less likely to use LTOT, as compared to
those diagnosed in years 2008-2010. We also observed a greater decline in LTOT use among
patients with TRD, as compared to those without TRD. Although comparable study findings do
not exist in the currently published literature, the discontinuation of LTOT over time has been
documented to be more pronounced among patients with substance-use disorders who are
deemed to be a high risk group.150 We speculate clinician initiated discontinuation may be higher
among adults with TRD, as they are recognized as a high-risk group, given their greater severity
of depression symptoms, higher risk of suicidal ideation and substance-use disorders55,56,138.
Therefore clinicians may decide to taper the use of LTOT because of lack of pain relief, opioid-
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related side effects, and adverse events including opioid dependence and misuse. 151 Such trends
are encouraging and may be due to increased attention to opioid abuse and awareness of their
risks in the past few years.152
However, the consistently higher LTOT use among adults with TRD over all time
periods suggests the need to closely monitor CNPC patients with MDD and TRD. Considering
the lack of robust evidence on the effectiveness of opioids for CNPC,33,34,53,129-131 and clinical
guidelines recommending against LTOT for chronic pain and MDD,55 future studies are needed
to identify the reasons for high rates of LTOT among TRD patients. Providers may need to
weigh the risks versus benefits of using LTOT in this patient population.
Additionally, our results also indicated that patient-level risk factors for LTOT identified
from our study, including male sex, age, higher number of CNPC, higher number of physical
health conditions, presence of anxiety disorders and, benzodiazepine use have also been
identified by other studies as risk factors for clinically recognized opioid dependence and abuse
among adults with CNPC.55,128,153 Providers need to assess risk factors while deciding
appropriate pain management strategies for patients with CNPC and MDD. Providing
collaborative multidisciplinary care for patients with CNPC, MDD and other chronic conditions
in an integrated setting (e.g. patient centered medical homes) can optimize interactions between
primary care providers and mental health specialists, improving patient outcomes.154 155
Additionally, behavioral interventions such as mindfulness-based or cognitive behavioral therapy
can be effective alternative strategies to manage patients with co-occurring chronic pain,
depression and other mental and physical health conditions.156
4.6 Limitations
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The study has several strengths, including availability of a large cohort of patients with
CNPC and MDD treated for depression in a real-world setting, and utilized a longitudinal study
design to track individuals over time, enabling assessment of temporal relationships. Our study
used a comprehensive algorithm that encompasses the four main strategies to overcome lack of
response, including optimization, switching, combination, and augmentation62,106 to identify
adults with TRD. To ensure robustness of study findings, the current study also tested the impact
of TRD on LTOT by varying the definitions of the study outcome. However, several limitations
should also be noted. First, TRD exists along a clinical continuum and there is a lack of
consensus on its definition. Although, the current study used a comprehensive claims-based
algorithm to define TRD mainly through pharmacy claims, a study relying on claims-based
information does not give comparable level of clinical information such as persistence of
depression symptoms, and tolerance to antidepressants. Further, lack of information on severity
of MDD, pain level, socio-economic status, and race/ethnicity may lead to unobserved selection
bias. It is plausible that our algorithm for identifying newly diagnosed episode of MDD (a lookback period of 180 days) may not truly capture all incident MDD patients. Furthermore,
prescription drug claims provide information only on filled prescriptions and not actual use.
Lastly, no direct inference should be made about the prevalence of TRD among adults with
CNPC and newly diagnosed MDD, given the specific inclusion /exclusion criteria of the study.
Although, our observed prevalence of 11.8% is consistent with some previously reported
estimates of TRD among adults with MDD obtained from other claims-based studies (6% to
15%).22,29,44,46
4.7 Conclusion
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The present study demonstrated that LTOT declined over time. Although the decline in
LTOT was greater in patients with TRD, LTOT rates were consistently higher among TRD
patients, as compared to those without TRD. Considering that patients with CNCP and MDD
who transition into TRD and continue to use LTOT are a high-risk group with substantial disease
burden, multidisciplinary and targeted behavioral approaches along with integrated care, may be
needed to co-manage CNCP and MDD.
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Figure 4.1. Schematic of the study design

Each individual was observed for 36 months with a 12-month baseline period, (cohort identification period where
adults with CNPC and newly diagnosed MDD were identified), 12- month TRD identification period and 12-month
post TRD –identification period (follow-up periods). LTOT was measured repeatedly every 180 days during the
baseline and follow-up periods, yielding a total of 6 repeated measures for each individual.
Abbreviations: MDD; Major depressive disorder; CNPC: Chronic non-cancer pain conditions; TRD: Treatment-resistant
depression; LTOT: Long-term opioid therapy

Figure 4.2. Schematic presentation of study sample selection

Attrition Flowchart
Total cases of MDD from January 1, 2008 through December 31,2016
(N=518,396)
Patients who were cancer free and had >2 diagnosis of any CNPC in 12 months before
MDD

(N= 154,304)
Patients without schizophrenia, schizoaffective disorders, other psychosis,
manic depression or bipolar disorder
(N= 147,403)
Patients with newly diagnosed MDD (No MDD diagnosis or antidepressant
prescription in prior 180 days)

(N=70,018)
Patients receiving antidepressant treatment (>1 antidepressant fill after MDD
diagnosis)
(N=52,384)
Final analytical sample: Patients aged >18 years with continuous enrollment 12
months before and 24 months after the MDD diagnosis date (index date)
(N=21,599)
Patients classified with TRD = 2,550;
Patients not meeting the definition of TRD = 19,049
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Table 4.1. Overall Baseline Sample Characteristics and Characteristics by use of LTOT among Adults with
CNPC and Newly Diagnosed MDD (measured during pre-index period)
Optum Clinformatics Real-World De-identified Data, 2007-2017

Characteristics
Age, Mean (SD)
Female
Age group
18-34 years
35-44 years
45-54 years
55-64 years
>65 years
Medicare Advantage Enrollment
Commercial
Medicare Advantage
Insurance plan type
HMO
PPO/POS
Other
Census region of residence
Northeast
Midwest
South
West
Index Year
Years 2008-2010
Years 2011-2013
Years 2014-2015
Type of CNPC
Back/Neck Pain (yes)
Arthritis/Joint Pain(yes)
Headache/Migraine (yes)
Neuropathic/other chronic pain
(yes)

Overall Sample
Use of LTOT
(N=21,599)
(N=3,561)
Percent
Percent
N
(%)
N
(%)
Personal factors

No use of LTOT
(18,038)
Percent
N
(%)

55.24 (17.51)
15,902
73.6

54.36 (17.94)
13,349
83.9

59.65 (14.30)
2,553
71.7

2,837
3,342
4,354
4,112
6,954

13.1
15.5
20.2
19.0
32.2

151
381
777
933
1,319

4.2
10.7
21.8
26.2
37

2,686
2,961
3,577
3,179
5,635

14.9
16.4
19.8
17.6
31.2

13,119
8,480

60.7
39.3

2,145
1,416

60.2
39.8

11,703
6,335

64.9
35.1

40.7
33.5
25.8

5,443
9,154
3,441

30.2
50.7
19.1

6,893
31.9 1,450
10,346
47.9 1,192
4,360
20.2
919
Environmental factors
2,001
5,363
8,684
5,551

7.1
19.8
45.5
27.5

254
705
1,621
981

P
value

Sig

<0.001
0.004
<0.001

***
**
***

<0.001

***

<0.001

***

<0.001

***

10.5
25.4
39.3
24.8

1,747
4,658
7,063
4,570

9.7
25.8
39.2
25.3

6,271
29
925
26.0
7,105
32.9 1,169
32.8
8,223
38.1 1,467
41.2
Health and illness related factors

5,346
5,936
6,756

29.6
32.9
37.5

<0.001

***

15,368
19,728
7,135

71.2
91.3
33

3,071
3,364
1,255

86.2
94.5
35.2

12,297
16,364
5,880

68.2
90.7
32.6

<0.001
<0.001
0.002

***
***
**

4,774

22.1

1,904

53.5

2,870

15.9

<0.001

***

<0.001

***

4,813
9,604
7,182

22.3
44.5
33.3

287
1,179
2,095

8.1
33.1
58.8

4,526
8,425
5,087

25.1
46.7
28.2

Number of physical chronic conditions b
0
8,947
1 to 2
7,566
>3
5,086

<0.001

***

37.4
36.0
26.6

902
1,446
1,213

25.3
40.6
34.1

8,045
6,120
3,873

44.6
33.9
21.5

No. of CNPC
1
2
>3

a
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Anxiety disorders(yes)
Sleep disorders(yes)
Substance use disorders (yes)
Obesity diagnosis (yes)
Polypharmacyc
Yes
No
Commonly used medications c
NSAIDS use
Benzodiazepine use

5,987
4,957
1,308
3,366

27.7
23.0
6.1
15.6

1,246
1,073
480
713

35.0
30.1
13.5
20.0

4,741
3,884
828
2,653

26.3
21.5
4.6
14.7

9,768
11,831

45.2
54.8

2,680
1,043

75.3
40.9

7,088
10,788

39.3
56.6

5,576
6,039

25.8
28.0

1,224
1,562

34.4
43.9

4,352
4,477

24.1
24.8

<0.001
<0.001
<0.001
<0.001

***
***
***
***

<0.001

***

<0.001
<0.001

***
***

Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain
conditions, HMO: Health Maintenance Organization, PPO: Preferred provider organization, POS: Point of service, other plan
type includes fee-for-service, indemnity plans, EPO (exclusive provider organization), GPO (Group purchasing organization),
IPP(individual program plan), and other plans, NSAID: Non-steroidal anti-inflammatory drugs, SD: Standard deviation, Sig:
Significance
Note: Based on 21,599 adults with CNPC and newly diagnosed MDD receiving antidepressant medication treatment who
were continuously enrolled during the observation period. LTOT as well as all baseline sample characteristics factors were
measured during the pre-index period (t2).
Long-term opioid therapy (LTOT) was defined as at least a > 90 days of continuous supply of prescription opioids within a
180 day period
a Number of CNPC conditions were obtained as sum of common chronic painful conditions such as back/neck pain,
headache/migraine, arthritis/joint pain, and neuropathic pain/other chronic pain conditions.
b Physical chronic conditions examined included conditions other than CNPC conditions such as asthma, coronary artery
disease, cardiac arrhythmias, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, diabetes,
hypertension, hyperlipidemia, osteoporosis, and stroke.
c Polypharmacy was defined as concomitant use of five or more medications within a 90 day period before the index date.
*** p < 0.001.; ** .001 ≤ p < .01; * .01 ≤ p < .05
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Figure 4.3. Percentage of LTOT use over time for all adults and by TRD status among
adults with CNPC and newly diagnosed MDD

Pre-Index

Post-Index

Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain
conditions, LTOT: Long-term opioid therapy
LTOT was defined as at least a > 90 days of continuous supply of prescription opioids within a 180-day period.
P values for percentage of LTOT use over time for all adults, adults with TRD and without TRD were <0.001
P values were obtained from unadjusted Generalized estimating equation models.
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Table 4.2: Unadjusted and Adjusted Odds Ratio and 95% Confidence Interval
from Generalized Estimating Equation (GEE) of TRD on Long -term opioid
therapy among
Adults with CNPC and Newly Diagnosed MDD
Optum Clinformatics Real-World De-identified Data, 2007-2017
Characteristics
Parameter
SE OR
95 % CI
P
Value
estimate (β)
Model 1: Unadjusted association between time and LTOT
Time
-0.055
0.003
<0.001
Model 2: Unadjusted Association of time and TRD with LTOT
TRD (Ref: No TRD)
Yes
0.56
0.043
1.76
[1.62, 1.91] <0.001
Time
-0.056
0.003
Model 2: Unadjusted Association of time, TRD, and interaction of time and TRD
with LTOT
TRD (Ref: No TRD)
Yes
0.62
0.050
1.85
[1.68, 2.04] <0.001
Time
-0.052
0.004
<0.001
TRD*Time
-0.022
0.020
0.037
Model 3: Adjusting for personal, environmental and health/illness related
factors a
Characteristics
Parameter
SE
AOR
95 % CI
P
Value
estimate (β)
TRD (Ref: No TRD)
Yes
0.44
0.050
1.55
[1.39, 1.71] <0.001
Time
-0.048
0.004
<0.001
TRD*Time
-0.033
0.012
0.006
Age Group (Ref :>65 years)
18-34 years
-0.18
0.179
0.86
[0.72, 1.02]
0.102
35-44 years
0.92
0.146
1.51
[1.31, 1.73] <0.001
45-54 years
1.49
0.123
1.87
[1.66, 2.10] <0.001
55-64 years
1.68
0.109
2.03
[1.84, 2.25] <0.001
Sex (Ref: male)
Female
-0.72
0.078
0.74
[0.69, 0.80] <0.001
Index Year (Ref: Years 2008-2010)
Years 2011-2013
-0.32
0.087
0.86
[0.79-0.94] <0.001
Years 2014-2015
-0.85
0.090
0.66
[0.61-0.72] <0.001
No. of CNPCb (Ref: 1 CNPC)
2
1.30
0.108
1.85
>3
3.25
0.112
4.20
Number of physical chronic conditions c (Ref: 0)

[1.65, 2.07]
[3.75, 4.69]

<0.001
<0.001

1 to 2
>3
Anxiety disorders (Ref No)
Yes
Sleep disorder (Ref: No)
Yes
Polypharmacy (Ref: No)
Yes
NSAIDs Use (Ref: No)
Yes

0.28
0.17

0.088
0.104

1.25
1.21

[1.14, 1.36]
[1.09, 1.34]

<0.001
<0.001

0.22

0.075

1.12

[1.04, 1.20]

0.001

0.25

0.078

1.08

[1.01, 1.17]

0.025

1.90

0.051

1.82

[1.75, 1.90]

<0.001

0.36

0.039

1.12

[1.08, 1.16]

<0.001
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Benzodiazepine use (Ref: no)
Yes

1.00

0.044

1.44

[1.38, 1.49]

<0.001

Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression,
CNPC: Chronic non-cancer pain conditions, NSAID: Non-steroidal anti-inflammatory drugs,
OR: Odds ratio, AOR: Adjusted odds ratio, CI: Confidence Interval
Note: Based on 21,599 adults with CNPC and newly diagnosed MDD receiving antidepressant
medication treatment who were continuously enrolled during the observation period.
Long-term opiod therapy was defined as at least a > 90 days of continuous supply of
prescription opioids within a 180-day period
a Only selected statistically variables are presented. The fully adjusted model adjusted for all
personal factors (age, sex, insurance plan type, Medicare Advantage Enrollment),
environmental factors (region of residence, index year), and health and illness factors (number
of physical chronic conditions, number of CNPC, presence of anxiety disorders, sleep
disorders, obesity, and medication use (polypharmacy, NSAID, and benzodiazepine use).
Polypharmacy, NSAIDs and benzodiazepines used as time varying variables and were
measured at all six time points.
b Number of CNPC conditions were obtained as sum of common chronic painful conditions
such as back/neck pain, headache/migraine, arthritis/joint pain, and neuropathic pain/other
chronic pain conditions.
c
Physical chronic conditions examined included conditions other than CNPC conditions such
as asthma, coronary artery disease, cardiac arrhythmias, congestive heart failure, chronic
kidney disease, chronic obstructive pulmonary disease, diabetes, hypertension, hyperlipidemia,
osteoporosis, and stroke.
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CHAPTER 5
5 Summary and Conclusion
5.1 Summary of Findings and Discussion
Treatment-resistant depression, commonly defined as insufficient response to multiple
antidepressant trials and augmentation strategies, 17-20 remains highly prevalent and exacts a
substantial clinical, economic, and humanistic burden among adults with MDD.20 Managing
TRD in patients with CNPC and MDD is even more challenging because of the complex bidirectional relationship between depression and pain, which often exacerbates one another, and
reduces benefits of depression and pain treatment.14,11,15 Existing literature on TRD has focused
on all adults with MDD. Owing to the lack of research on TRD among adults with CNPC and
MDD, we conducted this study to fill a critical knowledge gap and inform early interventions for
reducing the risk of transitioning to TRD.
Given that MDD and CNPC are both very costly conditions,8,11,157 and the presence of
TRD can further amplify this economic burden, it is important to estimate the incremental
economic burden associated with TRD. Estimating excess healthcare cost associated with TRD
can establish benchmarks for future cost of illness and cost-effectiveness studies, and can help in
translating the burden of illness into dollar terms, the universal language for healthcare decision
making.49 Many healthcare policy initiatives have shifted focus to the pursuit of triple aim of
improving health outcomes, quality of care and reducing healthcare costs. 48 This requires
identification of not only high-cost but also high-risk and high-need patients. Despite
recommendations against long-term opioid use among adults with CNPC and depression, LTOT
continues to be prescribed to adults with CNPC and MDD in real-world. 56,60,137,138 LTOT use
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among adults with TRD may make them a high-risk, high-need group as both LTOT and TRD
are independently associated with high risk of substance-use disorders, including abuse and
misuse of opioids, suicidal ideation and risk of hospitalizations. 20,22,54,139 Therefore, examining
the trajectory of LTOT among patients with CNPC and newly diagnosed MDD, and the
association of TRD with LTOT can inform clinical practice, payers, and policy makers in their
surveillance efforts of controlling opioid- related misuse and abuse in these patients.
Therefore, this dissertation pursued the following three related aims: 1) identifying
leading predictors of TRD among adults with CNPC and newly diagnosed MDD; 2) estimating
the direct economic burden associated with TRD and identifying factors that contribute to the
excess cost burden of TRD; and 3) examining the trajectory of LTOT use in adults with CNPC
and newly diagnosed MDD and how TRD can alter this trajectory. The current study, which
focuses on predictors and outcomes associated with TRD among patients with CNPC and MDD
is timely considering recent advances in the development of treatment options for TRD. After a
period in which it seemed that the innovation of antidepressants with new mechanisms of action
was going dry, the past decade has witnessed a renewed interest starting with the discovery of
antidepressant properties of ketamine and other newer investigational antidepressants.158 The
current study further highlights that there remains an unmet need for adequate treatment options
to manage chronic pain and TRD, and suggests that patient with TRD and CNPC have a
significant illness burden.
Leading Predictors of TRD among adults with CNPC and newly diagnosed MDD
We found that one in every nine adults with CNPC and newly diagnosed MDD
transitioned to TRD within one year of MDD diagnosis. As demonstrated in this study, a smaller
set of more easily assessed factors during the time of MDD diagnosis can be used to gauge the
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risk of transitioning to TRD. The leading predictors identified using robust machine learning
approaches included mental health specialist visits, use of psychotherapy after MDD diagnosis,
polypharmacy, age, presence of comorbid anxiety disorders, use of benzodiazepines, inpatient
status, index antidepressant class, and number of CNPC conditions. These factors may serve as
targets of further investigation or clinical intervention to improve treatment outcomes in this
population
Impact of TRD on direct economic burden
Adults with CNPC who transitioned from MDD to TRD had significantly higher direct
all-cause and MDD-related costs and healthcare resource utilization. Use of inpatient services
and prescription drug costs accounted for a significant portion of the total all-cause costs. It is
intuitive that adults with TRD will have higher prescription drug costs because of failure to
respond to multiple trials of antidepressants, higher illness burden due to the presence of other
chronic conditions, and higher use of polypharmacy. Our findings indicate that interventions
focused on reducing the risk of transitioning to TRD may have the potential to prevent inpatient
hospitalizations and can lead to cost savings for payers.
Factors contributing to the excess cost burden of TRD
Our findings indicated that 46% of the excess total costs among adults with TRD were
explained by differences in patient level characteristics such as polypharmacy, number of CNPC,
anxiety disorders, sleep disorders, and substance use disorders between the TRD and no TRD
groups. Therefore, potential cost savings associated with managing TRD may stem from
reducing the risk of polypharmacy, better co-management of chronic pain and co-occurring
substance use, anxiety, and sleep disorders.
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Trajectory of LTOT among adults with CNPC and MDD and association of TRD with
LTOT
Patients with TRD were significantly more likely to receive LTOT as compared to adults
with CNPC and MDD who did not meet the criteria for TRD at all time points during the 3 year
study period. The reasons for the higher use of LTOT among adults with TRD are not clear.
Future research needs to explore the reasons as to why TRD patients were more likely to receive
LTOT despite treatment guidelines recommending against the use of LTOT in subgroup of
adults with CNPC and MDD. Additionally, these findings further reinforce the need for specific
clinical guidelines for pain management with opioids among adults with CNPC and MDD who
meet the criteria for TRD and suggest that clinicians need to closely monitor the risks of using
LTOT in this subgroup.
On the other hand, we observed that LTOT use declined at a higher rate among adults
with TRD as compared to those without TRD in our study sample. These findings are
encouraging and suggest that clinicians may decide to taper and discontinue the use of LTOT
among adults with TRD perhaps due to lack of pain relief, higher risk of opioid –related side
effects and adverse events such as risk of addiction, opioid dependence and misuse.
5.2 Implications and Suggestions for Future Research
Our study findings suggest that an individual’s transition from MDD to TRD among
patients with CNPC can be predicted by information readily available in clinical settings such as
presence of comorbid anxiety disorders, history of inpatient hospitalization, younger age,
presence of higher number of CNPC, and indications of higher severity of MDD such as use of
psychotherapy, and mental health specialist visits. The study findings provide some actionable
evidence that can be utilized in real-world treatment decisions. For example, when a patient with
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CNPC and newly diagnosed MDD first visits a healthcare provider, the presence of these
characteristics may alert him/her to the possibility that the patient could develop TRD.
Monitoring patients with these characteristics more closely, using targeted individualized
treatment approaches, and using approaches such as augmentation strategies earlier in the
treatment process may reduce the risk of TRD. There is a need to shift the focus of care from
disease-specific to patient-centered care. The current study also highlights a huge unmet need for
management of TRD among patients with CNPC and MDD. As the focus on developing newer
treatment approaches for TRD is increasing in the past few years, 158 there is a need for studies
examining the efficacy and effectiveness of these medications on not only alleviating depression
symptoms but also pain symptoms. As MDD and chronic pain have overlapping neurobiological
pathways, they often respond to similar treatments and therefore, effectively managing one
symptom may also affect the other symptom. 14,15 Another important research implication is to
test the validity of the leading predictors obtained from the current study using other datasets.
Future studies also need to include a more comprehensive set of clinical variables that could not
be examined in the current study, including, levels of inflammatory cytokines, pain scores, and
psychological stress to identify predictors of TRD among patients with CNPC.
The current study is also the first study of its kind to estimate the direct economic burden
associated with TRD among adults with CNPC and MDD. Therefore, quantification of the
excess cost burden of TRD helps in translating the burden of illness into dollar terms which can
be used as input parameters for future cost-effectiveness studies. Our findings can also inform
payers and other stake-holders. As there is an emerging trend to focus on “value-based” care,
which emphasize on quality care at lower costs, alternative payment models such as bundled
payments, accountable care organizations, and medical homes are now increasingly used. As
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bundled payment models require risk adjustment to account for differences in beneficiary-case
mix,159 our findings suggest that an up to date estimate of economic burden for adults with MDD
should also include excess costs due to TRD. As TRD is associated with a significantly high
economic burden among patients with CNPC and MDD, our findings suggest that resource
allocation for MDD-related expenditures should be higher for patients with TRD.
The current study also highlights the patient level differences between adults with and
without TRD that contribute to the excess cost burden of TRD using post-decomposition
techniques. Our results suggest that the excess cost burden associated with TRD could be
reduced by adequately managing polypharmacy, chronic pain, comorbid sleep, anxiety and
substance-use disorders. Our findings suggest that interventions that have shown to reduce the
risk of polypharmacy such as systematic review of high risk medications, medication therapy
management, medication reconciliation, and using a multidisciplinary care approach114 have the
potential to off-set the excess costs due to polypharmacy. Furthermore, existing research shows
that the complex need of patients with multiple chronic conditions can be better managed
through healthcare delivery models using multidisciplinary and collaborative care approaches.
122,123 124

Therefore, patient-centered care by integrating mental and physical health in primary

care settings could improve treatment outcomes and potentially reduce costs associated with
TRD.
Our findings also provide clinical and policy implications regarding use of LTOT among
patients with CNPC and newly diagnosed MDD. Consistently higher LTOT use among adults
with TRD across all time periods suggests the need for providers to closely monitor patients for
the risk of opioid related side-effects and adverse events such as opioid misuse, abuse and
dependence. Providers may need to weigh the risks versus benefits of using LTOT in this patient
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population. Real-world findings on patterns of LTOT use among patients with CNPC and MDD
can further aid clinicians and policy makers in their surveillance efforts of combating the current
opioid crisis. Despite the increased rate of LTOT use among patients with CNPC and MDD, data
are lacking on the efficacy and safety of LTOT for CNPC, and particularly for patients with
MDD or substance abuse who are generally excluded from randomized trials.33 Additionally,
lack of data on efficacy and effectiveness of LTOT among adults with CNPC and TRD warrants
well-designed pragmatic trials to provide evidence on the effectiveness of LTOT use. There is
also a need for evidence-based clinical guidelines for use of LTOT in vulnerable groups such as
adults with CNPC and TRD. Our study findings also highlight the need for future studies to
ascertain clinical and patient-related reasons for high rates of LTOT use among patients with
TRD. Given, that a study by Scherrer et al. has reported that LTOT is a risk factor for TRD,30and
our study observed association of TRD with LTOT, future real-world studies are needed to
explore the bidirectional relationships between LTOT and TRD.
5.3 Strengths and Limitations
The study has several strengths, including availability of a large cohort of patients with
CNPC and MDD treated for depression in a real-world setting, and longitudinal study design to
track individuals over time, thereby enabling assessment of temporal relationships. Our study
used a comprehensive algorithm that encompasses the four main strategies to overcome lack of
response, including optimization, switching, combination, and augmentation62,106 to identify
adults with TRD. Additionally, the current study ensured robustness of study findings by
conducting sensitivity analyses, adjusting for observed selection bias through IPTWs, and using
advanced statistical techniques such as counterfactual-recycled predictions , two-part GLM
model, generalized estimating equations, and machine learning using random forest. The use of
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standardized prices for medical services, which adjusts for changes in payments based on local
factors, such as labor costs allowed for more accurate comparisons of spending on healthcare
services.160
Our study findings should be interpreted in the context of some limitations. First, the
study suffers from inherent limitations associated with claims data analysis, including coding
inaccuracies, absence of information on the severity of MDD, socioeconomic status,
race/ethnicity, physical activity, and social support. Second, TRD was defined using pharmacy
claims and ECT use and excludes other clinical considerations such as type of symptoms,
responsiveness to medical treatments, and tolerance to antidepressants which may under-estimate
or over-estimate the prevalence of TRD. Third, we may not have truly captured the actual use of
medication, as we could observe only presence of prescription claims. It is also plausible that by
limiting patients to only MDD diagnosis, we may have underestimated the prevalence of MDD
because MDD may at times could also be recorded using a general depression code. Finally,
although our study was not limited to including only working-aged adults, our results may not be
generalizable to other privately and publicly insured adults.
5.5 Conclusion
Overall, we identified that mental health specialist visits, polypharmacy (>5
medications), psychotherapy use, presence of comorbid anxiety disorders, and age were the five
leading predictors of TRD. TRD is associated with a high direct economic burden in terms of allcause and MDD-related costs and utilization among adults with CNPC and newly diagnosed
MDD. Additionally, we observed that LTOT rates were consistently higher among TRD patients
as compared to those without TRD across all time points; although the decline in LTOT was
greater in patients with TRD as compared to those without TRD. Although this study fills a
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critical knowledge gap, future research needs to confirm our study findings by including MDD
severity, pain scores, level of inflammatory biomarkers, social support, and other unobserved
factors such as income level, education, race and ethnicity that may affect the relationship
between TRD and economic and clinical outcomes. Future studies also need to incorporate these
factors when examining the risk factors of TRD among adults with CNPC and MDD. Our
findings suggest that use of multidisciplinary, collaborative, and targeted behavioral approach is
needed to not only better manage patients with CNPC and TRD who use LTOT but also to better
manage multimorbidity, polypharmacy, and to reduce the risk of inpatient hospitalizations. These
approaches can also have the potential to reduce the excess costs associated with TRD.
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Appendix 7.1. ICD-9/10 diagnosis codes used to identify CNPC, MDD and other chronic
conditions
Condition

ICD-9 code set used

ICD-10 code set used

Major Depressive
Disorders

296.2x - dysthymic disorder (major
depressive disorder-single episode)
296.3x- dysthymic disorder (major
depressive disorder, recurrent
episode)
309.0x - prolonged depressive
reaction
309.1x - prolonged depressive
reaction
300.4x- Adjustment disorder with
depressed mood
311.xx - depressive disorder, not
elsewhere classified

schizophrenia,
schizoaffective,
other psychotic
disorders related to
schizophrenia,
manic depression
or bipolar disorders
Back/neck pain

293.81, 293.82, 295,296.0, 296.1,
296.4, 296.5, 296.6, 296.7, 296.8,
296.9, 298

F320 - Major depressive disorder, single
episode, mild
F321 - Major depressive disorder, single
episode, moderate
F322 - Major depressv disord, single epsd,
sev w/o psych features
F323 - Major depressv disord, single epsd,
severe w psych features
F324 - Major depressv disorder, single
episode, in partial remission
F325 - Major depressive disorder, single
episode, in full remission
F328- Other depressive episodes
F3289 - Other specified depressive episodes
F329 -Major depressive disorder, single
episode, unspecified
F330 - Major depressive disorder, recurrent,
mild
F331 -Major depressive disorder, recurrent,
moderate
F332 - Major depressive disorder, recurrent
severe w/o psych features
F333 - Major depressive disorder, recurrent,
severe w psych symptoms
F3340- Major depressive disorder, recurrent,
in remission, unspecified
F3341 - Major depressive disorder,
recurrent, in partial remission
F3342 -Major depressive disorder, recurrent,
in full remission
F338 - Other recurrent depressive disorders
F339 - Major depressive disorder, recurrent,
unspecified
F341 - persistent depression
F432 – Stress induced depression
F20, F06.0, F06.2, F25, F21, F22, F23, F24,
F25.0, F25.1, F25.8, F28, F29, F31,

720.0, 721.3x – 721.9x, 722.2x,
722.30, 722.70, 722.80, 722.90,
722.32, 722.72, 722.82, 722.92,
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M45.9, M46.1, M49.80, M40, M46.90
M47, M48, M50.20, M50.30, M51
M50.00, M96.1, M961, M46.4, M50.80

722.33, 722.73, 722.83, 722.93,
724.xx, 737.1, 737.3, 738.4, 738.5,
739.2, 739.3, 739.4, 756.10, 756.11,
756.12, 756. 13, 756.19, 805.4,
805.8, 839.2, 839.42, 846, 846.0,
847.1, 847.3, 847.2, 847.9
721.0x, 721.1x, 722.0x, 722.31,
722.71, 722.81, 722.91, 723.XX,
839.0, 839.1, 847. 0

Headache/migraine

339.05,339.09, 339.10, 339.11,
339.12, 339.20, 339.3, 339.41,
339.42,339.43,339.44,339.81,
339.82, 339.83, 339.84, 339.85,
339.89, >346 and <347,
784.0,307.81

Arthritis/joint pain

710, 711,713, 714, 715, 716, 717,
718,719,725, 726, 727,728,729,730739

Neuropathic
pain/other chronic
pain

357, 337.0, 356.0, 356.2, 356.4,
356.9, 357.2, 357.3, 531.3, 723.4,
727.2, 338
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M50.90, M46.45, M48.02 M54.2, M53.0,
M53.1, M54.12, M54.13 M43.6, M54.02,
M67.88, M53.82, M48.00, M4804, M48.06
M48.08, M54.6, M54.5, M54.30, M54.14
M54.15, M54.16, M54.17, M54.89, M54.9
M43.2, M53.2, M53.3, M54.08, M43.8X9
M53.9, M96.2, M96.4Q7649,
Q76.2, Q76.49, Q76.419, Q76.49, S32009A
S12.9XXA, S32.009A, S32.10XA,
S32.2XXA
S338.XXA, S33.6XXA, S33.9XXA,
S13.4XXA
S13.8XXA, S23.3XXA, S23.3XXA,
S23.8XXA
S33.5XXA, S33.8XXA, S33.8XXA,
S23.9XXA
G44.85, G44.89, G43.109, G43.119,
G43.101
G43.111, G43.009, G43.019, G43.001,
G43.011,
G43.809, G43.A0, G43.B0, G43.C0,
G43.D0,
G43.819, G43.A1, G43.B1, G43.C1,
G43.D1,
G43.801, G43.811, G43.409, G43.419,
G43.401
G43.411, G43.829, G43.839, G43.821,
G43.831, G43.509, G43.519, G43.501
G43.511, G43.709, G43.719, G43.701
G43.711, G43.809, G43.819, G43.801
G43.811, G43.909, G43.919, G43.901,
G43.911,
G44.1, R51, G44.209
M32.10, M34.0, M341, M34.9, M35.0
M35.01, M00.10, M00-M02
M36.2, M36.3, M12.2, M12.3, M12.4,
M12.80, M12.80, M05,
M06, M08, M12.0, M33.20, M45, M48.8,
M15, M16, M17,M18 , M19, M12.1,
M12.1,M12.8, M12.9, M13.0,M13.1,
M13.8,M23.2, M23.3,M23.4, M23.5, M23.6,
M23.8,M23.9, M24,M43.4, M25,
M79.64,R29.89, R29.4, R26.2, M35.3,
M65,M61, M62, M63, M66, M67, M70M79,M85, M86,M87, M88.9, M89.00,
M899, M89.6, M89.7, M90-M93,M94.0,
M94.9
G60, G61.9, G61.0, G81.8, G62.0, G62.2,
G63, E08.42, E09.42, E10.42, G89

Appendix 7.2. Chapter 2. Study design for predicting treatment resistant depression among
adults with CNPC and newly diagnosed MDD
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Appendix 7.3. Chapter 2. Representation of development and testing of machine learning
model
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Appendix 7.4. Chapter 2. Components of the Algorithm for identification of patients with TRD
Component of TRD algorithm and the assigned score
At least 1 adequate trial of antidepressants, i.e. > 2 fills of same
antidepressant medication (1 point)
At least one extended duration, i.e. at least 3 fills of each antidepressant
medication (0.5 point)
Upward titration in dose (0.5 point)

N
19,740

Frequency
83.48%

17,557

74.25%

5,537

23.42%

Augmentation with atypical antipsychotics/mood stabilizer/thyroid hormone
(0.5 point for each augmentation strategy)
-Augmentation with atypical antipsychotics^
-With mood stabilizers (carbamazepine, lamotrigine, lithium, valproic acid)
-With thyroid hormone (liothyronine)
ECT use -considered directly as having TRD (4 points)
TRD (> 3 points)

782

3.31%

645
181
21
11
2,684

2.73%
0.77%
0.09%
0.005%
11.35%

No TRD
20,961
88.65%
Note: Based on 23,645 adults with CNPC and newly diagnosed episode of MDD using antidepressant
medications, with continuous enrollment for 2 years in a commercial insurance plan. Individual
components of TRD criteria will not add to 11.35% because an individual may satisfy one component of
the algorithm while failing to satisfy another component of the algorithm.
^ Medication names included in the class of atypical antipsychotics include aripiprazole, asenapine
maleate, brexpiprazole, cariprazine, clozapine, lurasidone, olanzapine, paliperidone, paliperidone
palmitate, quetiapine fumarate, risperidone, risperidone microspheres, and ziprasidone

Appendix 7.5. Chapter 2. Performance measures for the prediction models
Model
AUC Sensitivity Specificity
Out of bag error
Training set
Logistic Regression
Fully adjusted model (n=40) 0.711
0.482
0.811
N/A
Top 20 features 0.704
0.48
0.799
N/A
Random forest
Fully adjusted model (n=40) 0.716
0.52
0.9
11.42%
Top 20 features
0.7
0.4
1
11.51%
Testing set
Logistic Regression
Fully adjusted model (n=40) 0.708
0.576
0.801
N/A
Top 20 features 0.705
0.572
0.8
N/A
Random forest
Fully adjusted model (n=40) 0.704
0.48
0.99
11.47%
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Top 20 features

0.701

0.41

0.99

11.41%

Appendix 7.6. Chapter 3. Baseline patient characteristics of adults with CNPC and Newly
Diagnosed MDD by TRD status before and after Inversed Probability of Treatment
Weighting (IPTW), Optum Clinformatics DataMart, 2007-2017
Patients
Patients
Patients
Patients
classified
classified without
without
with TRD
with
TRD
TRD
(N=2,147)
TRD
(N=19,034)
(N=19,033)
(N=2,143)
%

%

P value

Wt. %

Wt. %

P value

Characteristics
Index Year

<0.001

0.870

2008-2010

23.1

23.3

23.4

23.3

2011-2013

38.7

33.3

34.3

33.8

2014-2016

38.1

43.5

42.3

42.9

Predisposing factors
Sex
Female

<0.001
77.0

73.3

Age group

0.705
74.1

73.7

<0.001

0.732

18-34 years

13.6

13.1

12.7

13.1

35-44 years

16.8

14.5

14.3

14.7

45-54 years

23.1

19.4

19.7

19.8

55-64 years

20.9

19.1

18.8

19.3

>65 years

25.6

34.5

33.1

33.9
Enabling factors

Medicare Advantage
Commercial
Medicare
Advantage
Insurance plan type

0.106

0.366

60.5

58.7

57.8

58.9

39.5

41.3

42.2

41.1

0.269

0.742

HMO

30.8

32.2

32.9

32.1

PPO/POS

48.5

46.8

46.2

46.9

Other

20.7

20.9

21.0

21.0
Need factors

No. of CNPC a

<0.001

0.844

1

18.7

23.2

23.2

22.8

2

40.7

45.0

43.9

44.5

>3

40.6

31.8

32.9

32.7

36.6

37.4

Number of physical chronic conditions
0
37.6

b

0.893
37.4
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0.112

1 to 2
>3
Anxiety disorders
Yes
No
Sleep disorders
Yes
No
Obesity diagnosis
Yes
No
Tobacco use disorders
Yes
No
Drug/alcohol use disorder
Yes
No

Census region of residence
Northeast

36.2

36.0

34.7

36.0

26.2

26.7

28.6

26.5

<0.001
55.7

36.1

44.3

63.9

0.527
38.8

38.1

61.2

61.9

<0.001

0.970

33.6

23.7

24.6

24.7

66.4

76.3

75.4

75.3

17.8

16.3

16.3

16.5

82.2

83.7

83.7

83.5

0.070

0.860

<0.001

0.910

14.9

11.1

11.4

11.5

85.1

88.9

88.6

88.5

<0.001
15.9
84.1

8.1
91.9
Environmental factors

0.830
8.8

8.9

91.2

91.1

0.156

0.870

10.1

8.9

9.6

9.0

Midwest

24.9

24.3

24.0

24.3

South

40.3

40.7

40.4

40.6

West

24.6

26.1

26.0

26.0

Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic
non-cancer pain conditions, HMO: Health Maintenance Organization, PPO: Preferred provider organization,
POS: Point of service, other plan type includes fee-for-service, indemnity plans, EPO (exclusive provider
organization), GPO (Group purchasing organization), IPP(individual program plan), and other plans, Wt.:
Weighted
Note: This sample includes adult patients with CNPC and newly diagnosed MDD who were continuously
enrolled in the medical and pharmacy obtained from the de-identified Optum Clinformatics DataMart. IPTW
weights were derived from a multivariate logistic regression on TRD status using the above predisposing,
enabling, need and environmental factors
a Number of CNPC conditions were obtained as sum of common chronic painful conditions such as back/neck
pain, headache/migraine, arthritis/joint pain, and neuropathic pain/other chronic pain conditions.
b Physical chronic conditions examined included conditions other than CNPC conditions such as asthma,
coronary artery disease, cardiac arrhythmias, congestive heart failure, chronic kidney disease, chronic
obstructive pulmonary disease, diabetes, hypertension, hyperlipidemia, osteoporosis, and stroke.
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Appendix 7.7. Chapter 3. Mean Annual IPTW Adjusted and Unadjusted All-Cause and MDD-Related Costs Among
Adults with CNPC and Newly Diagnosed MDD
Optum Clinformatics DataMart, 2007-2017
Patients
classified with
TRD

Patients
without TRD

Adjusted Incremental costs,
Model 1 a

Adjusted Incremental
Costs, Model 2 b

Unadjusted
Mean (SD), $

Unadjusted
Mean (SD), $

Mean $
(95% CI); P value

Mean $
(95% CI); P value

14,886
(42,737)

3,471
(3,436-3,504); <0.001

2,039
2,017 - 2,058); <0.001

5,909
(9,281)
7,285
(34,122)

3,953
(9,067)
5,720
(34,896)

1,362
(1,350-1,375); <0.001
1,240
(1,226 - 1,256); 0.011

773
(765 - 782); <0.001
903
(892 - 915); 0.148

5,024
(16,815)
ED
1,454
(4,237)
MDD-related healthcare costs (2018
US$)
Total medical costs
1,009
(5,067)
Inpatient
434
(3,842)
Outpatient
413
(2,610)
ED
162
(1,075)

4,046
(17,504)
1,169
(4,036)

764
(758 - 770); 0.008
231
(229 - 232); 0.002

637
( 637 - 643); 0.012
192
(190 - 193); 0.011

480
(3,774)
172
(2,880)
216
(1,855)
91
(873)

392
(387 - 397); <0.001
267
(263 - 271); <0.001
97
(95 - 99); <0.001
14
(13-15); 0.002

298
(293 - 303); <0.001
224
(220 - 228); <0.001
69
(68 - 71); <.001
12
(11-13); 0.005

Outcomes

All-cause healthcare costs (2018 US$)
Total
19,670
(41,965)
Prescription drug
costs
Inpatient
Outpatient

Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain conditions,
SD: Standard deviation; ED: Emergency Department
Note: The sample includes all eligible adults with CNPC and newly diagnosed MDD who are treated with antidepressants and were
continuously enrolled throughout the study observation period (N=21,180) from the de-identified Optum Clinformatics DataMart.
All the costs were standardized to 2018 US dollar. Total all-cause healthcare costs included the standardized costs for all healthcare
medical and pharmacy services paid by payers, including those for outpatient visits, inpatient stays, ED visits, and prescription
medications. Total MDD-related medical costs included costs for medical- related services including inpatient visits, outpatient and ED
visits. Total MDD-related costs were identified based on primary/secondary diagnoses of MDD.
Individual weights based on inverse probability of treatment weighting (IPTW) have been used for these analyses.
Unadjusted incremental costs and their corresponding P value and 95% CIs have been obtained using ordinary least square regressions.
a Incremental costs from Model 1 were measured using counterfactual recycled predictions performed using estimates obtained from a 2part GLM model with log link and gamma distribution which adjusted for baseline factors: predisposing factors (age, sex), enabling
factors (Medicare Advantage enrollment, type of insurance plan), need based factors (number of physical chronic conditions, number of
CNPC, presence of anxiety disorders, sleep disorders, obesity, and baseline medication use (polypharmacy, NSAID, opioid and
benzodiazepine use), and environmental factors (region).
b Incremental costs from Model 2 were measured using counterfactual recycled predictions performed using estimates obtained from a 2part GLM model with log link and gamma distribution which adjusted for all baseline factors mentioned in model 1 and healthcare costs.
a,b All P values and their confidence intervals were obtained using nonparametric bootstrap procedure (N=500) on the predicted values
obtained from recycled predictions.
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Appendix 7.8. Chapter 3. Mean Annual Adjusted and Unadjusted All-Cause and MDD-Related
Utilization Among Adults with CNPC and Newly Diagnosed MDD Treated with Antidepressants by TRD
status
Optum Clinformatics DataMart, 2007-2017
Patients classified with
Patients without TRD
TRD
N
Mean (number
N
Mean
Adjusted IRR a
Healthcare
(% with >1
of visits), (SD)
(% with >1
(number of
(95% CI) ; P value
resource
visit)
visit)
visits), (SD)
utilization
All-cause
Inpatient
480 (22.4%)
0.47 (1.28)
3,023 (15.9%)
0.30 (0.97)
1.30
(1.14 - 1.47) ; <0.001
Outpatient

1,636 (76.2)

8.04 (15.80)

12,953 (68.1%)

6.72 (16.82)

1.24
(1.15 - 1.34) ; <0.001

ED

857 (39.9%)

1.06 (2.40)

5,859 (30.8%)

0.71 (1.94)

1.21
(1.10 - 1.34) ; <0.001

MDD-related
Inpatient

77 (3.6%)

0.05(0.26)

198 (1.0%)

0.01 (0.12)

3.00
(2.15 - 4.18) ; <0.001

Outpatient

167 (7.8%)

3.86 (6.88)

625(3.3%)

2.41 (4.53)

2.95
(2.03 - 4.29); <0.001

ED

49 (2.3%)

0.03 (0.23)

154 (0.8%)

0.01 (0.13)

2.23
(1.52 - 3.29) ; <0.001

Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain conditions,
SD: Standard deviation; ED: Emergency Department; CI: Confidence Interval; IRR: Incidence rate ratio
Note: The sample includes all eligible adults with CNPC and newly diagnosed MDD who are treated with antidepressants and were
continuously enrolled throughout the study observation period (N=21,180) from the de-identified Optum Clinformatics DataMart.
MDD-related costs were identified based on primary/secondary diagnoses of MDD.
a Adjusted IRRs and their corresponding 95% CIs and P values were obtained using a generalized linear model (GLM) with a negative
binomial distribution (based on the results of the over-dispersion test). The model adjusted for baseline predisposing factors (age, sex),
enabling factors (Medicare Advantage enrollment, type of insurance plan), need based factors (number of physical chronic conditions,
number of CNPC, presence of anxiety disorders, sleep disorders, obesity, and baseline medication use (polypharmacy, NSAID, opioid
and benzodiazepine use), environmental factor (region), and baseline healthcare utilization.
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Appendix 7.9. Chapter 3. Unadjusted and Adjusted All-Cause Total and MDD-related Total Costs Over
Time Among Adults with CNPC and Newly Diagnosed MDD Treated with Antidepressants by TRD status
Optum Clinformatics DataMart, 2007-2017

Costs/
time

Patients classified
with TRD

Patients without
TRD

Mean $
SD $
Mean $
All-cause total healthcare costs (2018
US$)

Time 1
Time 2
Time 3
Time 4
Time 5
Time 6

8,268.9
6,876.9
7,967.2
7,122.5
6,998.8
6,808.9

20,831.6
15,536.1
18,791.7
15,316.3
21,185.4
18,199.2

5,195.9
5,195.7
6,191.7
5,074.2
4,654.0
4,914.9

538.5
339.6
524.0
348.4
199.8
168.1

5,787.4
3,484.5
3,347.7
3,944.7
1,757.0
1,783.6

83.0
95.3
254.3
87.7
67.2
63.2

Adjusted weighted cost
difference between TRD
and non-TRD groups b

β (time)= - 0.023;
P Value <0.001
β (TRD)= 0.35;
P Value <0.001
2389.33
2282.78
2180.22
2081.52
1986.54
1895.15
Average difference =
2135.92
β (time)= - 0.12;
P Value =0.007
β (TRD)= 1.37;
P Value <0.001
436.16
335.34
256.49
194.97
147.09
109.95
Average difference =
246.67

β (time)= - 0.017;
P Value =0.005
β (TRD)= 0.31;
P Value <0.001
1976.19
1881.69
1789.21
1698.7
1610.12
1523.45
Average difference =
1746.56
β (time)= - 0.052;
P Value =0.188
β (TRD)= 1.38;
P Value <0.001
449.51
365.81
294.51
218.63
162.36
120.97
Average difference =
268.63

SD $

18,404.8
17,152.4
27,304.4
26,925.9
17,284.4
17,037.6

MDD -related total medical costs (2018
US$)

Time 1
Time 2
Time 3
Time 4
Time 5
Time 6

Unadjusted weighted
cost difference
between TRD and
non-TRD groups a

3,548.9
1,657.5
4,956.6
2,051.8
1,784.9
1,287.7

Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain conditions, SD:
Standard deviation;
Note: The sample includes all eligible adults with CNPC and newly diagnosed MDD who are treated with antidepressants and were
continuously enrolled throughout the study observation period (N=21,180) from the de-identified Optum Clinformatics DataMart.
All the costs were standardized to 2018 US dollar. Total all-cause healthcare costs included the standardized costs for all healthcare medical
and pharmacy services paid by payers, including those for outpatient visits, inpatient stays, ED visits, and prescription medications. Total
MDD-related medical costs included costs for medical- related services including inpatient visits, outpatient and ED visits. Total MDDrelated costs were identified based on primary/secondary diagnoses of MDD.
a Unadjusted weighted incremental costs were obtained using counterfactual recycled predictions performed using estimates from
Generalized Linear Mixed Models (GLMM) with log link and gamma distribution.
b Adjusted weighted incremental costs were obtained using counterfactual recycled predictions performed using estimates from Generalized
Linear Mixed Models (GLMM) with log link and gamma distribution. which adjusted for time invariant factors including predisposing
factors (age, sex), enabling factors (Medicare Advantage enrollment, type of insurance plan), need based factors (number of physical
chronic conditions, number of CNPC, presence of anxiety disorders, sleep disorders, obesity), environmental factors (region) and time
varying factors including polypharmacy, NSAIDs, opioid and benzodiazepine use
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Appendix 7.10. Chapter 4. Components of the Algorithm for identification of patients with TRD
Component of TRD algorithm and the assigned score
At least 1 adequate trial of antidepressants, i.e. > 2 fills of same antidepressant medication (1
point)
At least one extended duration, i.e. at least 3 fills of each antidepressant medication (0.5
point)
Upward titration in dose (0.5 point)
Augmentation with atypical antipsychotics/mood stabilizer/thyroid hormone (0.5 point for
each augmentation strategy)
-Augmentation with atypical antipsychotic^
-With mood stabilizers (carbamazepine, lamotrigine, lithium, valproic acid)
-With thyroid hormone (liothyronine)
ECT use -considered directly as having TRD
TRD (> 3 points)
No TRD

N Frequency
(%)
84.48%
18,248
16,341

75.65%

5,124
732

23.72%
3.39%

606
166
20
11

2.81%
0.77%
0.09%
0.0005%

2,550
19,049

11.80%
88.20%

Note: Based on 21,599 adults with CNPC and newly diagnosed episode of MDD treated with antidepressants and are continuously enrolled
during the study observation period in a commercial insurance plan. Individual components of TRD criteria will not add to 11.35% because
an individual may satisfy one component of the algorithm while failing to satisfy another component of the algorithm.
^ Medication names included in the class of atypical antipsychotics include aripiprazole, asenapine maleate, brexpiprazole, cariprazine,
clozapine, lurasidone, olanzapine, paliperidone, paliperidone palmitate, quetiapine fumarate, risperidone, risperidone microspheres, and
ziprasidone
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Appendix 7.11. Chapter 4. Sample Characteristics by TRD Status among Adults
with CNPC and Newly Diagnosed MDD
Optum Clinformatics Real-World De-identified Data, 2007-2017

Characteristics

Patients
classified with
TRD (N=2,550)
Percent
N
(%)

Patients without
TRD (N=19,049)
N

Percent
(%)

P
value

Sig

<0.001

***

0.002

**

<0.001

***

Personal factors
Age, Mean (SD)
Female

53.75 (16.71)
1,941

76.1

55.43 (17.60)
13,961

73.3

Age group
18-34 years

328

12.9

2,509

13.2

35-44 years

446

17.5

2,896

15.2

45-54 years

568

22.3

3,786

19.9

55-64 years

536

21.0

3,576

18.8

672
Medicare Advantage Enrollment

26.4

6,282

33.0

Commercial

1,559

61.1

11,560

60.7

991

38.9

7,489

39.3

>65 years

Medicare Advantage

0.661

Insurance plan type
HMO
PPO/POS
Other

0.598
792

31.1

6,101

32.0

1,241

48.7

9,105

47.8

517

20.3

3,843

20.2

Environmental factor
Census region of residence
Northeast

0.084
268

10.5

1,733

9.1

Midwest

647

25.4

4,716

24.8

South

1,002

39.3

7,682

40.3

West

633

24.8

4,918

25.8

Years 2008-2010

750

29.4

5,521

29

Years 2011-2013

847

33.2

6,258

32.9

Years 2014-2015

953

37.4

7,270

38.2

Index Year
0.740

Health and illness related factors
Type of CNPC
Back/Neck Pain (yes)

1,933

75.8

13,435

70.5

<0.001

Arthritis/Joint Pain(yes)

2,353

92.3

17,375

91.2

0.073

Headache/Migraine (yes)
Neuropathic/other
chronic pain (yes)
No. of CNPC a

991

38.9

6,144

32.3

<0.001

701

27.5

4,073

21.4

<0.001

1

453

17.8

4,360

22.9

2

1,042

40.9

8,562

44.9

<0.001
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***
***
***
***

>3

1,055

Number of physical chronic conditions
0
1,028

41.4

6,127

32.2

b

0.380
40.3

7,919

41.6

1 to 2

898

35.2

6,668

35.0

>3
Anxiety disorders(yes)

624

24.5

4,462

23.4

940

36.9

5,047

26.5

<0.001

***

Sleep disorders(yes)

763

29.9

4,194

22.0

<0.001

***

Obesity diagnosis (yes)

430

16.9

2,936

15.4

0.058

Polypharmacy c
Yes
No
Commonly used medications

1,507

59.1

8,261

43.4

1,043

40.9

10,788

56.6

<0.001

***

c

NSAIDS use

717

28.1

4,859

25.5

0.005

**

Benzodiazepine use

961

37.7

5,078

26.7

<0.001

***

Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC:
Chronic non-cancer pain conditions, HMO: Health Maintenance Organization, PPO: Preferred
provider organization, POS: Point of service, other plan type includes fee-for-service, indemnity
plans, EPO (exclusive provider organization), GPO (Group purchasing organization),
IPP(individual program plan), and other plans, NSAID: Non-steroidal anti-inflammatory drugs,
SD: Standard deviation, Sig: Significance
Note: Based on 21,599 adults with CNPC and newly diagnosed MDD receiving antidepressant
medication treatment who were continuously enrolled during the observation period. All baseline
factors were measured in the 12-month period before the index date. The first TRD date was used
as the index date for patients classified as having TRD and for those classified as non-TRD
patients, a pseudo index date was randomly selected based on the TRD index date.
a Number of CNPC conditions were obtained as sum of common chronic painful conditions such
as back/neck pain, headache/migraine, arthritis/joint pain, and neuropathic pain/other chronic
b
pain conditions.
Physical chronic conditions examined included conditions other than CNPC conditions such as
asthma, coronary artery disease, cardiac arrhythmias, congestive heart failure, chronic kidney
disease, chronic obstructive pulmonary disease, diabetes, hypertension, hyperlipidemia,
osteoporosis, and stroke.
c Polypharmacy was defined as concomitant use of five or more medications within a 90 day
period before the index date.
*** < p < 0.001; ** .001 ≤ p < .01; * .01 ≤ p < .05
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Appendix 7.12. Chapter 4. Percentage of LTOT use (defined as continuous opioid supply
for >120 days) over time for all adults and by TRD status among adults with CNPC and
newly diagnosed MDD

Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain
conditions, LTOT: Long-term opioid therapy.
LTOT was defined as at least a > 90 days of continuous supply of prescription opioids within a 180-day period.
P value for percentage of LTOT use over time for all adults, adults with TRD and without TRD was <0.001
P-values were obtained from unadjusted Generalized estimating equation models.
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Appendix 7.13. Chapter4. Unadjusted and Adjusted Odds Ratio and 95% Confidence
Interval from Generalized Estimating Equation (GEE) of TRD on Long -term opioid
therapy (defined as continuous opioid supply for >120 days) among
Adults with CNPC and Newly Diagnosed MDD
Optum Clinformatics Real-World De-identified Data, 2007-2017
Characteristics
Parameter
SE
OR
95 % CI
P Value
estimate (β)
Model 1: Unadjusted association between time and LTOT
Time

-0.056

0.003

-

-

<0.001

Model 2: Unadjusted Association of time and TRD with LTOT
TRD (Ref: No TRD)
Yes
Time

0.56

0.045

1.75

-0.057

0.004

-

[1.60, 1.91]

<0.001

-

Model 2: Unadjusted Association of time, TRD, and interaction of time and TRD with
LTOT
TRD (Ref: No TRD)
Yes

0.63

0.052

1.87

[1.68, 2.07]

<0.001

Time

-0.052

0.004

-

-

<0.001

TRD*Time

-0.029

0.011

-

-

0.011

Model 3: Adjusting for personal, environmental and health/illness related factors a
Characteristics
TRD (Ref: No TRD)
Yes

AOR

95 % CI
[1.41, 1.75]

P Value

0.45

0.055

1.57

<0.001

Time

-0.049

0.004

-

-

<0.001

TRD*Time

-0.041

0.013

-

-

0.001

Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic
non-cancer pain conditions, NSAID: Non-steroidal anti-inflammatory drugs, OR: Odds ratio, AOR:
Adjusted odds ratio, CI: Confidence Interval
Note: Based on 21,599 adults with CNPC and newly diagnosed MDD receiving antidepressant medication
treatment who were continuously enrolled during the observation period.
Long-term opioid therapy was defined as at least a > 120 days of continuous supply of prescription opioids
within a 180-day period
a Only selected significant variables are presented. The fully adjusted model adjusted for all personal
factors (age, sex, insurance plan type, Medicare Advantage Enrollment), environmental factors (region of
residence, index year), and health and illness factors (number of physical chronic conditions, number of
CNPC, presence of anxiety disorders, sleep disorders, obesity, and medication use (polypharmacy,
NSAID, and benzodiazepine use). Polypharmacy, NSAIDs and benzodiazepines used as time varying
variables and were measured at all six time points.
b Number of CNPC conditions were obtained as sum of common chronic painful conditions such as
back/neck pain, headache/migraine, arthritis/joint pain, and neuropathic pain/other chronic pain conditions.
c Physical chronic conditions examined included conditions other than CNPC conditions such as asthma,
coronary artery disease, cardiac arrhythmias, congestive heart failure, chronic kidney disease, chronic
obstructive pulmonary disease, diabetes, hypertension, hyperlipidemia, osteoporosis, and stroke.
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